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The Theoretical Modeling, Design, and Synthesis of Key Structural Units for Novel 
Molecular Clamps and Pro-Apoptotic Alpha Helix Peptidomimetics  
 
Stephanie Tara Weiss 
ABSTRACT 
 
This dissertation presents the theory and practice of designing, synthesizing and 
using peptidomimetics to disrupt protein-protein interactions.  Our general strategy is to 
design and synthesize peptidomimetics that will mimic peptide secondary structures (α-
helices and β-sheets).  Chapter One is a theoretical examination of the feasibility of using 
β-sheet mimics called molecular clamps to inhibit substrate-receptor interactions by 
blocking the substrate rather than the receptor or enzyme.  Several natural and synthetic 
examples of this approach are given in support of this concept.  We also present the 
results of a kinetic modeling study and a consideration of which types of systems would 
be the best candidates for a substrate-targeted inhibitor approach. Chapter Two relates a 
continuation of previous work in our lab to synthesize five novel β-protected hydrazino 
amino acids.  These hydrazines are essential precursors for synthesizing constrained β-
strand mimetics.  We showed that we could selectively deprotect the α-nitrogen of the 
hydrazines, and we synthesized several novel examples of polar β-protected hydrazino 
amino acids.  Chapter Three discusses the design and synthesis of small-molecule and 
peptidomimetic MDM2 inhibitors, including our work on synthesizing a new class of α-
helix mimics that have improved water solubility compared with previously reported 
  xiv 
 
examples of α-helix mimics.  As with the constrained β-strand mimics described in 
Chapter Two, the synthesis of novel hydrazino amino acid precursors is a key step in 
synthesizing our α-helix mimics.  One isoleucine hydrazine derivative was synthesized, 
and progress was made toward synthesizing two other hydrazines from tryptophan.  In 
addition, the synthesis of three potential small-molecule inhibitors of MDM2 is 
described.  Chapter Four describes the use of the GLIDE program to design and evolve 
an α-helix mimic that will interact with the pro-apoptotic protein Bax.  Progress toward 
the synthesis of this compound is also reported.   
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CHAPTER ONE 
 
GENERAL INTRODUCTION: PROTEINS AND THEIR INTERACTIONS 
 
 
1.1 Proteins, Peptides, and Peptidomimetics 
 
Proteins and peptides are biopolymers comprised of monomers called amino 
acids.  There are twenty naturally occurring amino acids, and they are linked together by 
amide bonds to form linear chains.  Shorter chains of less than 40 amino acids are called 
peptides, while longer chains are called polypeptides or proteins (1). 
The linear amino acid sequence of a protein is called its primary structure.  A 
protein’s primary structure is ultimately responsible for the structure and function of that 
protein.  However, proteins are also organized on additional levels based on the local and 
global folding of the polypeptide chain.  Local folding gives rise to the protein’s 
secondary structures and occurs due to hydrogen bonding among amino acids.  Two 
common secondary structures are the α-helix and the β-sheet (1). 
An α-helix is a spiral shape that occurs due to hydrogen bonding between the 
carbonyl group of one amino acid and the amine group of another amino acid located 
four positions up the chain.  The hydrogen bonds are oriented parallel to the axis of the 
helix, while the side chains of the amino acids point out approximately perpendicularly.  
See Figure 1.1A below (1).  Beta sheets resemble a pleated piece of paper, and are also 
held together by hydrogen bonds between the carbonyl and amino groups of different 
amino acids.  The hydrogen bonds lie within the plane of the pleats, while the amino acid 
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side chains are oriented perpendicular to the peptide backbone both above and below the 
plane of the pleats.  See Figure 1.1B (1). 
 
 
 
 
 
 
Figure 1.1A: Structure of an Alpha 
Helix (1).  Hydrogen bonds in an α-
helix are parallel to the helical axis, 
while the amino acid side chains are 
oriented perpendicularly. 
 
Figure 1.1B: Structure of a Beta Sheet (1).  
The peptide backbone forms the pleated 
sheet, while the amino acid side chains stick 
out above and below it. 
   
 
Proteins also have a global folding conformation that comprises their tertiary 
structure.  The α-helices, β-sheets, and other local folding patterns interact with one 
another to form the overall shape of the protein (1).  Although infinite possible protein 
conformations are possible, each protein must be folded correctly in order to be capable 
of performing its biological function.  This function often entails interaction with other 
proteins (2).  The importance of protein-protein interactions has only recently become 
appreciated, along with the possibilities for interfering with protein-protein interactions in 
order to probe biological systems and develop new therapeutics (3).   
There are several ways in which protein-protein interactions might be prevented.  
One obvious possibility is to screen for or design a small organic molecule inhibitor.  
Small molecule inhibitors are often effective in cases where the binding residues of the 
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protein are clustered together or there is a known natural product inhibitor (3).  However, 
since the size of a protein is very large compared with a typical natural product or 
synthetic organic inhibitor, it may be difficult to block the entire protein surface by using 
small molecules.  There is also the possibility that there may be no binding pocket on the 
surface of a flat protein to which a small organic inhibitor could bind; the surface of 
many proteins is flat (3). 
A second possibility is to use inhibitors that are actual peptides with the same 
sequence as the portions of the protein that interact with other proteins.  Such peptides 
serve as competitive inhibitors of the proteins whose binding sites they resemble.  This 
strategy was successfully used to inhibit several examples of protein-protein interactions, 
including HIV-1 protease dimerization, herpes simplex virus ribonucleotide reductase 
dimerization, and p53/HDM2 interactions (3).  However, this strategy tends not to work 
well in cases where amino acid residues from noncontiguous parts of the protein’s 
primary sequence must come together to form an epitope that is then capable of 
interacting with another protein (3).  In addition, peptides tend to have limitations in 
terms of poor bioavailability and metabolic stability in living organisms (3), as well as 
poor pharmacokinetics and potential side effects due to a lack of selectivity (4). 
However, the peptide-based strategy is not limited merely to making an exact 
copy of the binding peptide portion of the protein of interest.  The chemical and 
biological properties of inhibitory peptides can be modified by incorporating non-natural 
amino acids into their sequence, or by even dispensing with the peptide’s amide-based 
backbone altogether (3).  Such modifications give rise to yet another possible source of 
inhibitors called peptidomimetics.   
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Peptidomimetics have peptide-like structures and activities.  However, since they 
do not have actual peptide bonds, the pharmacokinetic properties of peptidomimetics are 
modified.  This allows peptidomimetics to interact with receptors and enzymes 
analogously to their parent peptides while avoiding many of the problems that arise from 
using actual peptides (4).  One of the best-known examples of a peptidomimetic is 
morphine, an opiate receptor agonist (4).  Unlike most peptide-peptidomimetic pairs, the 
peptidomimetic morphine was known long before the natural enkephalin peptide ligands 
of the opiate receptors were discovered (4).  The structures of Leu-enkephalin and 
morphine are shown in Figure 1.2. 
 
OH
NH2
NH
O
NH
O
NH
O
NH
O
COOH
Leu-enkephalin
OH
O
OH
N
morphine
 
 
Figure 1.2: Leu-Enkephalin, a Natural Peptide Ligand of Opiate Receptors, and 
Morphine, an Opiate Receptor Peptidomimetic (4).  The analgesic activity of 
morphine has been known for over 2000 years, but the natural peptide enkephalin ligands 
were not discovered until the 1970s. 
 
  
Unlike morphine, most peptidomimetics are purposefully designed based on the 
structure of their parent peptides (4).  Farmer’s Rules describe a systematic method for 
converting a peptide into a peptidomimetic (4).  These rules include using the simplest 
possible active portion of the peptide (the pharmacophore), maintaining the steric 
parameters of the parent peptide, beginning with a flexible molecule and then 
progressively constraining it through several rounds of structure-activity relationship 
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studies, and mimicking the three-dimensional shape of the parent peptide, particularly 
with regard to α-helices and β-sheets (4).  
This dissertation presents the theory and practice of designing, synthesizing and 
using peptidomimetics to disrupt protein-protein interactions.  In general, our strategy for 
doing this is to design and synthesize peptidomimetics that will mimic peptide secondary 
structures (α-helices and β-sheets).  The remaining portion of Chapter One is a 
theoretical examination of the feasibility of using β-sheet mimics called molecular 
clamps to inhibit substrate-receptor interactions by blocking the substrate rather than the 
receptor or enzyme.  Several natural and synthetic examples of this approach are given in 
support of this concept, and a kinetic modeling study is presented. Chapter Two relates a 
continuation of previous work in our lab to synthesize β-protected hydrazino amino 
acids.  These hydrazines are essential precursors for synthesizing constrained β-strand 
mimetics.  Chapter Three summarizes the current literature concerning the design and 
synthesis of α-helix mimics, to block the interaction between p53 and MDM2.  It also 
describes our work on synthesizing a new class of α-helix mimics that have improved 
water-solubility compared with previously reported examples of α-helix mimics.  As 
with the constrained β-strand mimics described in Chapter Two, the synthesis of 
hydrazino amino acid precursors is a key step in synthesizing our α-helix mimics.  
Chapter Four describes the use of molecular modeling and docking software to design an 
α-helix mimic that will interact with the pro-apoptotic protein Bax.  Also, the ongoing 
synthesis of one compound that showed promise in the computer screening is reported. 
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1.2 Molecular Clamps: Background 
 
The canonical strategy for blocking enzyme-substrate or receptor-ligand 
interactions is to screen for or design a small molecule or peptide that can bind to the 
enzyme or receptor in such a way as to inhibit that enzyme or receptor.  This inhibition 
can either be competitive, where it is targeted to the active site, or noncompetitive, where 
it is targeted to a separate allosteric site.  Both types of inhibition share the same general 
strategy, however, which is to prevent the enzyme or receptor from conducting its normal 
activity.  This strategy has lead to multiple successes in drug discovery and continues to 
do so, as exemplified by recent reports of retinoic acid analogs that inhibit retinoic acid 
receptors (5) and inhibitors of cyclin-dependent kinases (6). 
However, this strategy is not suitable in all cases, because many enzymes catalyze 
reactions on more than one substrate.  Blocking such enzymes leads to the undesired 
effect of blocking other pathways that may not be involved in the mechanism whose 
modulation is desired.  One recent example of the potential bad outcome due to the 
inhibition of promiscuous enzymes is farnesyltransferase and geranylgeranyltransferase 
inhibitors intended to prevent prenylation of K-Ras (7).  Inhibition of K-Ras prenylation 
is desirable for cancer therapy; however, use of farnesyltransferase-specific inhibitors 
will not prevent prenylation of K-Ras by geranylgeranyltransferase, and use of dual-
purpose prenylation inhibitors is toxic to the point of complete lethality (7). 
One possible way to solve this problem is to take the complementary approach, 
which entails having the inhibitor bind to the substrate instead of to the enzyme or 
receptor.  Rather than having the inhibitor compete with the substrate for the enzyme’s 
active or allosteric site, the inhibitor competes with the enzyme to bind the substrate, 
 7
analogous to the way antibodies recognize and neutralize their antigens (8).  Thus, the 
substrate binds to the inhibitor, and this prevents that particular substrate from being 
acted upon by the enzyme.  However, the enzyme is left free to continue to perform its 
functions on all other substrates (8).  Figure 1.3 is a schematic comparing the effects on a 
dual-substrate enzyme of using no inhibitor (top panel), a traditional enzyme-targeted 
inhibitor (middle panel), or a substrate-targeted inhibitor (bottom panel). 
 
 
  
Figure 1.3: Schematic of the Substrate-Targeted Inhibitor Concept (8).  The top 
panel shows two substrates (squiggles) interacting with the same enzyme (block) in the 
absence of inhibitor.  The middle panel shows an inhibitor (triangle) that targets the 
enzyme, thereby blocking all functions of that enzyme.  The bottom panel shows an 
inhibitor (boomerang) that targets one substrate (left squiggle), leaving the enzyme free 
to continue catalyzing its reaction with the second substrate (right squiggle).  
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There is good reason to believe that this approach of inhibiting the substrates 
rather than the enzymes or receptors would be successful based on the prevalence of both 
natural and synthetic examples in the literature.  Some of the natural precedents include 
not only antibodies, but also antibiotics in the vancomycin family.  The vancomycin 
group antibiotics are cell wall synthesis inhibitors in bacteria, but their mechanism of 
action is quite different from that of the penicillins, which also inhibit cell wall growth 
(9).  The penicillins accomplish this task by binding to and inhibiting the penicillin-
binding proteins (PBPs), which are a group of enzymes required by the bacterium to 
synthesize its cell wall (10).  Thus, the penicillins are examples of enzyme-targeted 
inhibitors, as shown in the middle panel of Figure 3.  The vancomycin group antibiotics, 
in contrast, complex with the peptidoglycan precursors needed to synthesize the bacterial 
cell wall, but do not affect the PBP enzymes (9).  Thus, they function analogously to the 
substrate-targeted inhibitor portrayed in the bottom panel of Figure 3.  The fundamentally 
different strategies for inhibiting cell wall synthesis by the penicillins versus the 
vancomycins explains why bacteria that have developed resistance to the penicillins may 
still be susceptible to the vancomycins, and vice versa (9). 
The use of antibodies themselves in this context is an obvious approach, and 
several examples of antibodies are in clinical use (11).  While therapeutic use of 
antibodies has multiple advantages, including high specificity, long half-life, and lack of 
resistance, antibodies also have serious disadvantages in that they can be immunogenic or 
toxic, and they have limited ability to cross the blood-brain barrier or penetrate solid 
tumors (11,12).  Some of these problems may be solved through the use of human 
recombinant antibodies rather than murine ones (11,12).  In addition, several approaches 
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using small molecules rather than antibodies have been published (8).  However, small 
molecules have problems of their own, one of which is that they have fewer interactions 
with the substrate as compared to polypeptides (8).  Thus, several techniques have been 
developed that attempt to remedy this by mimicking antibody-antigen interactions and 
creating a multivalent inhibitor capable of recognizing multiple epitopes on the target 
substrate protein (8).   
One such technique involves using double synthetic peptides linked together to 
form “molecular forceps” that were shown to be specific for the carboxy terminus of 
hRas  (8,13).  These forceps consisted of two tetrapeptides connected by either a flexible 
or a rigid linker (13).  The peptides on each arm of the forceps were identical, increasing 
the collective binding affinity of the conglomerate for the substrate analogous to an 
antibody’s two identical epitope-binding sites (8).  Large numbers of potential forceps 
were synthesized and screened using combinatorial chemistry procedures previously 
developed (13).  In addition, active forceps were found to contain multiple Lys residues, 
either as part of the linker or as part of the forceps sequence (13).  Testing for binding of 
other Ras sequences showed that the molecular forceps were specific for the particular 
hRas sequence; other substrates continued to be farnesylated in the presence of the 
forceps (13).  It was found that binding resolution as sensitive as a single amino acid 
could be obtained using molecular forceps, precluding the need for complex 
macromolecular structures (13).  However, the IC50 values for the best molecular forceps 
were on the order of 100 µM, and improvement in their affinity is necessary before they 
could be used in a therapeutic context (13).  The authors also were concerned that their 
forceps might not be capable of penetrating cell membranes (13). 
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A second group used a similar approach where multiple identical pentapeptides 
were attached to library beads, which were then used to screen for a dopamine D2 
receptor target sequence that was attached to magnetic beads (8,14).  This approach had 
the additional advantage that the bound inhibitor-substrate complexes could be easily 
isolated using a magnet to pull them to the side of the tube, while unbound ligand beads 
would simply settle to the bottom (8).  This was the first example where small peptide 
ligands were found that bind to a small peptide target molecule (14).  Binding affinity 
was better for this bead-to-bead technique, with the best Kd values on the order of 100 
nM  (14). 
Molecular clamps (MCs) function slightly differently than these previously 
reported strategies.  They prevent substrates from being posttranslationally modified by 
binding only to the specific substrate sequence upon which an enzyme acts, thus 
preventing the active site of the enzyme from being able to interact with and catalyze that 
substrate.  Each MC consists of 12 amino acid residues connected by a peptidomimetic 
linker.  Functioning as a β–turn mimic, the MC itself undergoes a change in conformation 
from a random coil when unbound, to form a small, stabile β–sheet upon binding the 
target sequence.  MCs can be designed to have affinity for any known substrate site of 
posttranslational modification.  The approach has the added advantage of only requiring 
knowledge of the enzyme’s activity and the substrate sequence that the enzyme modifies, 
but not the structure of the enzyme or its active site.  A schematic of the mechanism of 
MC activity is shown in Figure 1.4.  The remainder of this chapter describes the 
applications and considerations needed to use the MC strategy.   
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Figure 1.4: Schematic of the Binding of a Substrate by a MC.  The substrate protein 
has multiple sequences of amino acids, but only one sequence that is specific for the MC 
(A).  Binding of the MC to the substrate to form a three-stranded β-sheet occurs in a two-
step process, where first one side of the clamp binds (B), followed by rapid binding of the 
second side (C). 
 
1.3 Molecular Clamps: A Model 
Classical enzyme kinetics systems are comprised of an enzyme (E) and a substrate 
(S).  The enzyme and substrate react to form an enzyme-substrate complex (E·S).  The 
E·S complex can either dissociate back to enzyme and substrate, or it can go on to form 
the product (P).  Km, the Michaelis-Menton constant, describes the propensity for E·S 
complex dissociation to occur.  If an enzyme-targeted inhibitor (I) is present in the 
system, it will react with the enzyme to form an enzyme-inhibitor (E·I) complex, thereby 
tying up some of the enzyme and giving rise to an E·I dissociation constant called Ki.  All 
of these relationships are shown in Figure 1.5. 
The Michaelis-Menton equation describes the rate (v) at which an enzymatic 
reaction will occur for a given concentration of substrate: 
Vmax [S]
Km + [S]
v = 
 
 The reaction rate also depends on the maximum rate at which the enzyme can catalyze 
the reaction (Vmax), as well as on Km. 
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Figure 1.5: Dissociation Constants for a Classical System with an Enzyme-Targeted 
Inhibitor.  Ki is the dissociation constant for the enzyme-inhibitor complex, and Km is 
the dissociation constant for the enzyme-substrate complex.  See the text for the 
definitions of the remaining variables. 
 
However, the presence of a substrate-targeted inhibitor like the MC complicates 
this scenario considerably.  This is because the enzyme can only act upon the free 
substrate ([S]free), but the MC would sequester some of the substrate and make it 
unavailable for binding.  The enzyme binds to the remaining free substrate similarly to 
the previous scenario.  However, rather than binding to the enzyme like the classical 
inhibitor does, the MC binds directly to the substrate instead, giving rise to a new 
dissociation constant (KMC).  These relationships are shown in Figure 1.6. 
KMC
E   +   S E   +   P 
+
MC
E S
MC S
Km
 
Figure 1.6: Dissociation Constants for a MC Substrate-Targeted Inhibitor.  Km is the 
dissociation constant for the enzyme-substrate complex, and KMC is the dissociation 
constant for the inhibitor-substrate complex.  See the text for the definitions of the 
remaining variables. 
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The total amount of substrate is equal to the sum of the free substrate and the MC-
substrate complex: 
[S]total = [S]free + [S•MC] 
The concentration of free substrate depends on the concentration of MC, as well as on the 
binding affinity of the MC for the substrate: 
[S]free  = ½[{([MC]total - [S]total + KMC)2 + 4KMC[S]total}0.5 - ([MC]total - [S]total + KMC)] 
Since only the free substrate is available to be catalyzed by the enzyme, [S]free must be 
substituted for [S] in the Michaelis-Menton equation: 
Vmax [S]
Km + [S]free
v = 
free
 
Substituting the formula for [S]free into the Michaelis-Menton equation gives a revised 
version of the Michaelis-Menton equation that can be used to study the kinetics of a 
system comprised of an enzyme, a substrate, and a MC.  This equation was then 
manipulated to study the effects of the MC on enzyme kinetics. 
There are four potential variables that can be studied using this model: the 
concentration of substrate ([S]), the concentration of MC inhibitor ([MC]), the binding 
constant of the enzyme for the substrate (Km), and the binding constant of the MC for the 
substrate (KMC).  Changing each of these variables affects the expected outcome of the 
model in predictable and logical ways.  In each graph, the reaction velocity was plotted as 
the percentage of the actual velocity compared to the maximum velocity. 
 If the concentration of substrate is increased beyond a certain point, it is expected 
that the ability of the MC to sequester the substrate would be overpowered; this 
conclusion is supported by the model.  See Figure 1.7A.  When all other variables are 
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held constant, a high enough concentration of substrate (> 1 mM) will allow the enzyme 
to reach its maximum velocity, assuming that the enzyme has a Km in the low micromolar 
range and the MC is also present in a low micromolar concentration.  The model suggests 
that once the substrate and MC are present in approximately a 1:1 ratio, the usefulness of 
the MC begins to diminish.  This is true even in a scenario like the one shown in Figure 
1.7A, where the MC has a much higher binding affinity for the substrate than the enzyme 
does.  In contrast, if the [MC] is at least an order of magnitude greater than the total [S], 
then the MC will be effective at removing most or all of the free substrate from the 
system and  inhibiting formation of the E·S complex. 
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Figure 1.7A: Effect of Substrate Concentration on Relative Enzyme Velocity.  A 
sufficient concentration of substrate will overpower the MC.  [MC] = 5 µM, Km = 30 µM, 
KMC = 50 nM. 
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Effect of Molecular Clamp Concentration on Relative Enzyme Velocity
0
10
20
30
40
50
60
70
80
90
100
0.00E+00 1.00E-06 2.00E-06 3.00E-06 4.00E-06 5.00E-06 6.00E-06
[MC]
%
 V
m
ax
 
 
Figure 1.7B: Effect of Molecular Clamp Concentration on Relative Enzyme 
Velocity.  A sufficient concentration of MC will sequester the substrate and prevent 
catalysis.  [S] = 1 nM, Km = 30 µM, KMC = 50 nM. 
  
 Increasing the concentration of MC was predicted to decrease the relative enzyme 
velocity, and this was indeed found to be the case.  If the substrate/MC ratio is 
approximately 1:1, inhibition is relatively low, and the enzyme reaction velocity is 
relatively close to normal.  It is not until the [MC] gets about three orders of magnitude 
higher than [S] that catalysis is essentially blocked.  Again, this scenario assumes that the 
MC has a higher affinity for the substrate than the enzyme does. 
The activity of an enzyme that binds tightly to its substrates is considerably less 
affected by the presence of the MC compared with an enzyme that does not, assuming 
that excessive concentration of substrate is not present.  This can clearly be seen by 
comparing the velocities of several enzymes with different Km values while holding the 
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concentrations of substrate and MC and the KMC constant.  If the Km of the enzyme were 
sub-nanomolar, the MC would likely not be able to effectively compete with it, as noted 
previously, unless its own binding constant was also sub-nanomolar.  See Figure 1.7C. 
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Figure 1.7C: Effect of Km Value on Relative Enzyme Velocity.  As the enzyme’s 
affinity for the substrate increases, it is able to out-compete the MC for the substrate.  
[MC] = 5 µM, [S] = 1 nM, KMC = 50 nM 
 
 
Finally, the binding affinity of the MC also plays an important role, with the 
effectiveness of the inhibition increasing as the affinity of the MC for the substrate 
increased when all other factors were held constant.  A molecular clamp present at high 
nM concentrations with a KMC of 1 mM was not able to affect the rate of substrate 
catalysis by the enzyme.  Similarly, the MC with a KMC of 1 µM had only a minimal 
effect.  However, when the KMC dropped to 1 nM, catalysis was dramatically decreased 
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even at these low concentrations of inhibitor; a KMC of 1 pM essentially prevented 
catalysis altogether, as shown in Figure 1.7D.  These results were also in line with our 
expectations. 
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Figure 1.7D: Effect of KMC Value on Relative Enzyme Velocity.  As the MC’s binding 
affinity improves, the MC becomes more effective at sequestering the substrate and 
preventing catalysis.  [S] = 1 nM, Km = 30 µM, [MC] = 95.9 nM. 
 
 
Based on these model results, it is reasonable to conclude that MCs would be 
most useful in systems where the concentration of the substrate is low, the affinity of the 
enzyme for the substrate is low (high Km), and the affinity of the MC for the substrate is 
high (low KMC).  It is also beneficial to raise the concentration of MC as high as is 
feasible within pharmacokinetic and toxicological limits. Consideration must be given to 
the concentration of the substrate that is naturally present in cells in order to select the 
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substrate candidates likeliest to be successfully inhibited using MCs.  If the substrate to 
be inhibited is normally present at low concentrations, then the amount of MC needed to 
inhibit it will also be low, and within an achievable range.  However, if the substrate is 
present in large amounts in cells, then the concentration of MC needed to inhibit that 
substrate may be prohibitively high or toxic.  Thus, substrates present in large amounts 
are not likely to be good candidates for inhibition by MCs. 
 Since MCs are essentially peptides with a small peptidomimetic region, one 
possible problem that might limit their use is membrane impermeability.  Proteins and 
peptides are not generally able to penetrate cell membranes.  However, it is also known 
that there are various techniques that can be used to allow peptides to enter cells, and that 
certain peptide sequences are themselves readily transferred across cell membranes along 
with any proteins attached to them (12,16,17).  The most important feature of these 
peptides appears to be the inclusion of multiple basic residues in them, particularly 
arginine (16,17).  Such guanidine-containing sequences could easily be incorporated into 
MCs as well, facilitating their uptake into cells.  Successful penetration of fusion proteins 
has already been demonstrated with a number of other peptide examples (17).  Membrane 
permeability can also be increased through palmitoylation, myristoylation, or other 
addition of long-chain hydrophobic groups to the peptide (18). 
 There is also the issue of peptide stability to proteases.  As with the issue of cell 
membrane penetration, chemical modification of the MC by conjugating it with a 
polymer is one possibility (19).  Such conjugation has the added advantage of reducing 
the immunogenicity of the peptide (19).  It is also possible to increase the peptidomimetic 
character of the MCs as needed if degradation of its peptide bonds is a major problem. 
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 Finally, the biochemistry and pharmacology of MCs are not known.  Since the 
intracellular MC-bound substrate will not necessarily be degraded, such substrates could 
function as undesired inhibitors of other metabolic pathways.  It is also unknown whether 
MCs will be toxic to the kidneys or other organs where they might accumulate.  These 
questions require answers before the MC strategy could be used in a clinical scenario.  
 In conclusion, we have considered the pros and cons of using MCs as drugs, as 
well as established some guidelines to determine which enzymes would be the best 
candidates for the use of MCs.  We also performed some virtual kinetics studies on a 
hypothetical system where we varied the MC concentration, the substrate concentration, 
the enzyme-substrate dissociation constant, and the MC-substrate dissociation constant to 
see how each of these changes would affect the usefulness of the MC.  Future work on 
this project would involve designing and synthesizing some actual MCs that target a 
carefully selected substrate, as well as performing biological tests to increase our 
knowledge of the behavior of MCs with respect to their ability to penetrate cells and their 
pharmacological properties. 
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CHAPTER TWO 
 
SYNTHESIS OF POLAR AND NONPOLAR HYDRAZINO AMINO ACIDS 
 
 
2.1 Introduction 
 
2.1.1 Hydrazines 
 
Hydrazines are compounds that contain a nitrogen-nitrogen single bond.  The first 
hydrazine synthesis to be reported in the chemical literature was for phenylhydrazine in 
1875 by Emil Fischer (1).  Ordinary hydrazine was synthesized about a decade later by 
Theodor Curtius (1).  The physical, chemical, and biological properties of hydrazine and 
its derivatives are well documented.  These compounds are surprisingly common in 
nature, as well as from synthetic sources such as agriculture, industry, military and space 
vehicle fuels, and even medicinal drugs (1).  
The use of over thirty hydrazines as drugs is especially interesting in light of the 
fact that the majority of hydrazines studied thus far are known to be toxic, teratogenic, 
and carcinogenic (1,2).  However, it is not unprecedented for antineoplastic agents to also 
be carcinogens.  Mustard gas, alkylating compounds, cyclophosphamide, and several 
other antineoplastic agents are also known to both induce and inhibit cancer (2).  The 
exact mechanism of action of the antineoplastic hydrazines is not known, but they are 
postulated to be cytotoxic, interfere with glycolysis and gluconeogenesis, chelate 
essential trace metals, inhibit mitosis, and/or degrade DNA (2).  
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Most hydrazine-containing drugs are heterocyclic compounds, and they exhibit a 
wide range of activities (1).  A sample of hydrazine-containing drugs includes several 
anti-hypertensives (pheniprazine, hydralazine), anti-depressants (nialamide, marplan), 
cancer chemotherapeutics (procarbazine and proresid, along with hydrazine itself), 
Parkinson’s disease chemotherapeutics (carbidopa), anti-viral drugs (methiazone), anti-
tuberculotics (isoniazid, phtivazid), and antibiotics (sulfaphenazole, sulfamethizole), 
among others (1,2).  
Hydrazine derivatives have also been tested as inhibitors of enzymes that 
metabolize α-amino acids (3,4).  Some of these compounds have been shown to be 
potent, specific inhibitors of such enzymes in bacteria, giving rise to a class of hydrazines 
with antimicrobial activities.  One well-studied example is a class of diaminopimelic acid 
(DAP) analogs.  These compounds were found to inhibit the enzyme meso-DAP D-
dehydrogenase in B. sphaericus and the enzyme LL-DAP epimerase in E. coli, thereby 
preventing these bacteria from synthesizing the amino acid lysine and interfering with 
their cell wall synthesis (4).   
More recently, a series of hydrazine-containing peptides were reported that inhibit 
the enzyme DAP aminotransferase in E. coli (5).  The authors were able to observe good 
in vivo antimicrobial activity from some of their compounds when they coupled their 
hydrazines to normal amino acids to make short peptides.  They speculated that the 
presence of the natural amino acids would allow their compounds to be transported into 
the cells as peptide prodrugs that would then be cleaved intracellularly via a peptide 
transporter.  However, they found that some of the transportable peptides were not active, 
 24
which suggests that the regular amino acids may actually play a role in the inhibitory 
properties of the active compounds (5). 
2.1.2 Synthesis of Hydrazines 
 
There are several methods to synthesize hydrazines that have been reported in the 
literature.  Before 1970, there were basically three methods that had been reported: 
reduction of the hydrazone of an α-keto acid, functionalization of a carbonyl compound 
(analogous to the Strecker synthesis), and reaction of hydrazine with an α-halo acid (6).  
Reduction of hydrazones was achieved using sodium and mercury to give the free 
hydrazine (7).  This procedure is shown in Scheme 2.1.  The Strecker-like synthesis, 
shown in Scheme 2.2, involves the use of hydrazine and potassium cyanide to give the 
cyanohydrazine.  This can then be hydrolyzed to the hydrazino acid (6). 
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Scheme 2.1: Reduction of a Hydrazone to a Hydrazine (7).  This procedure gives the 
racemate of the hydrazine. 
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Scheme 2.2: Strecker-Like Synthesis of a Hydrazino Acid (6).  This procedure also 
gives the racemate of the hydrazine. 
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  These two methods could not be used to form optically pure isomers; only the 
reaction of hydrazine with an α-halo acid procedure was useful in synthesizing α-
hydrazino acids (6).  This method involves reacting the α-hydrazino acid with hydrazine 
via a bimolecular nucleophilic substitution reaction.  Since the α-carbon is already 
functionalized in this case, an optically active product can be obtained (8, 9).  Two 
examples of this reaction are shown in Scheme 2.3. 
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Scheme 2.3: Reaction of Hydrazine with an α-Halo Acid (8,9).  This procedure can be 
used to obtain an optically active hydrazine.  Z denotes the Cbz protecting group. 
 
 
 
Subsequently, it was discovered that hydantoic acids could be rearranged into 
hydrazines using sodium hypochlorite (10).  Substituted hydroxylamines had been used 
previously to form nitrogen-nitrogen bonds, but since excess amine was required, the 
purification of the products was difficult (10).  The synthesis route involved reaction of 
the amino acid with potassium cyanate to form the hydantoic acid.  The hydantoic acid 
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was then reacted with sodium hypochlorite to form the hydrazine (10).  However, the 
yield of the rearrangement reaction was relatively low, between 20-30% (11).  More 
recently, it was found that using potassium hypochlorite instead of sodium hypochlorite 
could raise the yield of this method to around 70% (11).  The synthesis of hydrazines via 
rearrangement of hydantoic acids is depicted in Scheme 2.4. 
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Scheme 2.4: Synthesis of a Hydrazine via Rearrangement of a Hydantoic Acid (10).  
This procedure gives an optically pure product. 
 
These authors had also attempted to make hydrazines via two other methods (10).  
One procedure that they tried was to react an amino acid with hydroxylamine-O-sulfonic 
acid, which theoretically should have given the hydrazino acid directly (10).  However, 
they were not able to separate the hydrazine product from the amine starting material; this 
was a major problem because the parent amine had to be used in excess (10), as shown in 
Scheme 2.5.  They also tried N-aminating an optically active acetylated amino cyanide 
(10).  This approach was successful, giving the optically active acetylated hydrazino 
cyanide, which could then be hydrolyzed to the hydrazino acid (10).  This reaction is 
shown in Scheme 2.6.  
Another group found that they were able to synthesize optically active hydrazines 
from 2-(((4-nitrobenzene)sulfonyl)oxy) (nosyloxy) esters via a bimolecular nucleophilic 
substitution mechanism (12).  The nosyloxy compounds were made by reacting 2-
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hydroxy esters with nosyloxy chloride, followed with Boc-protected hydrazine, to give 
the Boc-protected hydrazine (12).  This procedure is shown in Scheme 2.7. 
 
 
NH2OSO3NaO
HO
NH2
COOH X O
HO
NHNH2
COOH
 
 
Scheme 2.5: Attempt to Synthesize a Hydrazine Using a Hydroxylamine Derivative 
(10).  The hydrazine product was obtained, but it could not be readily purified from the 
parent amine. 
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Scheme 2.6: Synthesis of a Hydrazine Via N-Amination (10).  This method gives an 
optically active product. 
 
Several groups successfully synthesized optically active hydrazines via 
asymmetric electrophilic amination (13-16).  This is a complementary approach to 
several of the previous procedures described where the hydrazine or its synthon served as 
the nucleophile (14).  In contrast, asymmetric electrophilic amination uses the carbon 
skeleton as the nucleophile and the nitrogen-containing compound as the electrophile 
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(13-16).  The electrophilic hydrazine synthon used was di-tert-butyl azodicarboxylate 
(DBAD) (13,14); this particular azodicarboxylate was chosen because it was found that a 
bulkier alkyl group improves the diasteroselectivity of the reaction (15).  In addition, 
DBAD is stable and commercially available, and the tert-butoxy group can be removed 
from the hydrazine by conditions that will not affect the N-N hydrazine bond (16).  Some 
examples of hydrazine formation via electrophilic amination are shown in Scheme 2.8. 
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Scheme 2.7: Synthesis of a Hydrazine from a Nosyloxy Ester (12).  The nosyloxy 
esters are made from chiral hydroxy esters. 
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Scheme 2.8: Hydrazine Formation Via Asymmetric Electrophilic Amination (13, 
14).  This procedure is complementary to previous procedures that used hydrazine as the 
nucleophile. 
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A few groups have also synthesized hydrazines by reacting amino acids with 
oxaziridines (17-20).  The oxaziridines themselves are produced by reacting a Schiff base 
with a peracid like oxone (18-20), or by electrophilic amination of a carbonyl compound 
(17).  Although N-amination is needed to produce hydrazines from oxaziridines, 
oxaziridines are well-known aminating agents that can also be used to attach nitrogen 
atoms to nucleophilic carbon atoms, sulfur atoms, oxygen atoms, and even phosphorus 
atoms (17,19).  In addition, the synthesis of oxaziridines with protecting groups that are 
amenable to peptide synthetic methods made this methodology useful for the synthesis of 
peptides and peptidomimetics (18).  Oxaziridines have been synthesized with Boc (18-
20), Cbz (19), Fmoc (19), and other protecting groups on them.  Some examples of 
protected hydrazines synthesized by reacting an amine with an oxaziridine are shown in 
Scheme 2.9. 
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Scheme 2.9: Synthesis of Hydrazines Using Oxaziridines (17,20).  Several stable 
oxaziridines like the second example shown have been synthesized. 
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 Recently, we published a method to synthesize hydrazines from amino acids by 
the reduction of nitrosamines (21,22).  The amino acid is first converted to a nitrosamine, 
and this is then reduced using Zn/conc. HCl at –78 °C.  The free hydrazine is reactive and 
has a tendency to self-condense, so we protected the free β-nitrogen using Boc anhydride 
(21,22).  This procedure was very successful for the synthesis of the Boc-protected 
hydrazines of several nonpolar amino acids (21,22). 
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Scheme 2.10: Synthesis of Hydrazines from Amino Acids Via Nitrosamines (21).  
After formation of the hydrazine, it was immediately reacted with Boc anhydride to 
protect it as the stable Boc derivative. 
 
 
 
2.1.3 Use of Hydrazines in Peptidomimetics 
 
Hydrazines are the key structural units of both azapeptide and hydrazinopeptide 
peptidomimetics.  Azapeptides are isosteres of peptides where the alpha carbon has been 
replaced with a nitrogen atom.  The first reported azapeptide, an analog of the peptide 
hormone angiotensin II, is shown in Figure 2.1 (23).  The authors found that this 
compound was about 100-fold less active than angiotensin II, but its duration of activity 
was twice as long (23).  Another azapeptide with an unnatural N-cyclohexyl substituent 
was found to be an excellent inhibitor of HIV protease (24).  More recently, azapeptides 
were studied as anti-cancer agents (25). 
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Figure 2.1: Example of an Azapeptide (23).  This is the first reported example in the 
literature of an azapeptide isostere.  The azapeptide portion of the molecule is boxed. 
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Figure 2.2: Examples of Hydrazides (26-28).  In a hydrazide, the hydrazine is coupled 
to the rest of the peptoid by its β-nitrogen.  The hydrazines in each molecule are boxed. 
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Azapeptides are easier to synthesize in comparison with hydrazinopeptides.  One 
reason is that the chiral alpha carbon has been replaced with an achiral nitrogen atom.  In 
addition, there are fewer problems with regioselectivity in coupling the nitrogens to make 
an azapeptide (26).  However, hydrazinopeptides, where the normal α-amino acid is 
replaced with an α-hydrazino amino acid, more closely mimic the three-dimensional 
structure of real peptides.  There are two groups of hydrazinopeptides that are classified 
based on how the hydrazine subunits are coupled to the rest of the molecule (26).  
Hydrazides are coupled by the β-nitrogen, whereas N-amino amides are coupled by the 
α-nitrogen (26).  Some examples of hydrazides and N-amino amides are shown in 
Figures 2.2 and 2.3, respectively (26-29). 
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Figure 2.3: Examples of N-Amino Amides (26, 28).  In N-amino amides, the hydrazine 
is coupled to the rest of the peptoid by its α-nitrogen.  The hydrazines in each molecule 
are boxed. 
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2.1.4 Use of Hydrazines in β-Sheet Mimics 
 
Proteins are ubiquitous in biology, and there is consequently a great deal of 
interest in interfering with their interactions as well as mimicking their secondary 
structures.  The use of peptidomimetics is also considered to be a way to overcome the 
disadvantages inherent in using peptides as drugs, such as poor bioavailability, enzymatic 
degradation, antigenicity, and high cost of production (29).  The hydrazines described in 
this chapter can be used as structural subunits for conformationally restricted peptide 
secondary structures like α-helices and β-sheets.  This section briefly describes the 
construction of β-sheet mimics, while α-helix mimics are described in Chapter Three. 
Peptide ligands must adopt a specific conformation in order to interact with their 
receptors.  There is a tremendous loss of entropy that occurs when a flexible ligand in 
solution is forced to interact in a single conformation with a protein such as a receptor 
(30).  In general, processes where a large number of torsional motions become restricted 
upon binding are unfavorable due to entropic factors, even if they are enthalpically 
favored (30).  Thus, it would be advantageous to conformationally restrict such peptide 
ligands in order to reduce entropic losses, as this would be expected to increase their 
binding affinity. 
To this end, our group has been working on the construction of two units that 
mimic the extended conformation of a peptide by constraining the peptide as part of a 
six-membered ring (22).  The first diagram in Figure 2.4 shows a regular peptide that is 
free to rotate around its single backbone bonds.  There are five such dipeptide (DP) 
bonds, numbered DP1 to DP5.  Forming a six-membered dipeptide unit (DPU) ring as in 
the middle diagram constrains two of these DP bonds and prevents any rotation around 
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them.  Beyond this, using a hydrazine as in the right-hand azadipeptide (ADP) structure 
forms two six-membered rings; now there are four constrained DP bonds.  We are 
currently working on the synthesis and testing of constrained ADP-type peptidomimetics 
using our amino hydrazines. 
 
 
 
 
 
 
 
 
Figure 2.4: Constraining the Extended Conformation of a Peptide to Mimic a Beta 
Sheet.  (22)  The first figure shows a regular peptide in an extended conformation.  All of 
the dipeptide (DP) bonds are bolded.  The middle figure shows a partially constrained 
dipeptide unit (DPU), where a six-membered ring prevents the peptide from rotating 
around DP bonds 2 and 3.  The figure on the right shows a completely constrained 
azadipeptide (ADP) unit, where the peptide is prevented from rotating around DP bonds 
2, 3, 4, and 5. 
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Figure 2.5: Some Constrained Hydrazine-Containing Peptidomimetics (31, 32).  The 
ring size can be six-membered, as in the second example, or much larger. 
 
 
There are some examples in the literature where hydrazines have been used to 
construct conformationally restricted peptidomimetics.  One is a mimic of the CD4 loop 
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region that prevents the HIV glycoprotein gp120 from binding to CD4 on human 
lymphocytes (31).  Another group synthesized a six-membered ring with a hydrazine 
(32).  These two structures are shown in Figure 2.5. 
2.2 Results and Discussion 
 
This work builds on our group’s previous work to synthesize the hydrazines of 
five nonpolar amino acids: valine, isoleucine, leucine, methionine, and phenylalanine 
(21,22).  Initially, the synthesis of compounds 6a-6e, shown in Scheme 2.12, was 
attempted using our previously developed methodology (21,22), shown in Scheme 2.11.  
However, we ran into trouble at several key points during the synthesis, such that two 
new procedures were necessary.  One change was to use a single-step reductive 
amination rather than a two-step procedure to benzylate the amino groups.  Second, the 
successful synthesis of Lys compound 6b required the use of oxaziridine 10 rather than 
the nitrosamine reduction pathway used for the other four amino acids reported here.   
Our original procedure begins with the protection of the methyl ester of the amino 
acid as the benzyl amino ester.  This was done via a two-step process that involved 
forming the imine using benzaldehyde and the amino acid methyl ester, isolating the 
imine, and then reducing it to the benzyl amine using sodium borohydride.  The final 
compounds were made by converting each benzyl amine to the corresponding 
nitrosamine using tert-butylnitrite, reducing the nitrosamine with zinc and concentrated 
HCl at –78 °C, and protecting the β-nitrogen of the hydrazine by reacting it with Boc 
anhydride neat (21,22).  The original procedure is depicted in Scheme 2.11. 
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Scheme 2.11: Procedure for the Synthesis of Five Protected Nonpolar Amino Acids 
(21, 22).  This work was the starting basis for the synthesis of the four polar amino acid 
and alanine hydrazines described in this chapter. 
 
 
The general synthetic procedure used to synthesize the analogous alanine, lysine, 
serine, threonine, and tyrosine hydrazines is shown in Scheme 2.12.  This synthesis 
begins with the reductive amination of the free amine 1a-e using benzaldehyde, 
triethylamine, and sodium cyanoborohydride to give compounds 2a-e.  The benzyl-
protected amines were then treated with tert-butyl nitrite to give nitrosamine compounds 
3a-e in high yield and purity.  The nitrosamines were reduced using Zn/conc. HCl to give 
the reactive intermediate hydrazines 4a-e, which were immediately reacted with Boc 
anhydride to give the stable, Boc-protected hydrazines 5a-e.  Finally, the benzyl 
protecting group was removed from the α-nitrogen via hydrogenolysis to give 
compounds 6a-e.  Lysine compound 5b could not be obtained by this method, and was 
synthesized by an alternative procedure as discussed below. 
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Scheme 2.12: Synthesis of the Ala (6a), Lys (6b) Ser (6c), Thr (6d), and Tyr (6e) Boc-
Protected Hydrazines from the Free Amines (1a-e).  Compound 1a was commercially 
available, while compounds 1b-1e were synthesized as described below.  Compound 5b 
could not be obtained by this procedure. 
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Scheme 2.13: Unsuccessful Two-Step Method for Synthesizing Compound 2a.  
Unlike the other nonpolar amino acids published previously, the Ala compound 2a could 
not be obtained using this two-step method. 
 
The two-step benzylation method shown in Scheme 2.11 was successfully used 
for all five nonpolar amino acids attempted previously.  Therefore, we began our 
synthesis of the new hydrazine examples by attempting to protect the corresponding free 
amines with a benzyl group using the two-step process (21,22).  However, we ran into 
some difficulties with the synthesis of several of the new benzyl amino acids.  One 
problem was that we were unable to obtain the alanine benzyl amine 2a using the two-
step procedure, even after multiple attempts, as depicted in Scheme 2.13.  Instead, only 
benzyl alcohol was isolated as evidenced by TLC and NMR.   
Amino acid imine stability studies have shown that bulkier side chain amino acids 
like Leu and Ile provide greater protection against imine hydrolysis when compared with 
smaller groups (33).  This would explain why the two-step procedure worked for the 
larger nonpolar amino acids but not for Ala.  However, since reduction of the imine 
apparently occurs faster than hydrolysis during the one-step reduction, we were able to 
successfully obtain 2a by that route.  Further conversion of 2a to the protected hydrazine 
6a was performed by the usual procedures. 
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Second, we had trouble benzyl-protecting the polar amino acids due to the 
racemization of the alpha carbon, as depicted in Scheme 2.14.  Initially, we did not know 
about this problem because in most cases, racemization would produce a pair of 
enantiomers, which would not be detectable.  However, when the imine of threonine was 
reduced to the benzyl amine, we were clearly able to detect two stereoisomers.  This is 
due to the presence of a second chiral center in the side chain of threonine that does not 
exist in any of the other four amino acids.  Thus, when the alpha carbon of threonine 
racemized, we could clearly detect two diastereomers by TLC, and they could be 
separated by column chromatography.   
An examination of the NMRs of the two diastereomers shows that they are very 
similar, but the groups of protons have slightly different coupling constants.  This can be 
seen in Figure 2.6.  The aromatic protons in 2d, the (L)-isomer, show up as a multiplet 
ranging from 7.22-7.38 ppm.  In contrast, the aromatic protons of the (D)-isomer 13b are 
more closely overlapping, with the multiplet for the aromatic protons ranging from 7.24-
7.35 ppm.  The benzyl CH2 protons appear as a multiplet ranging from 3.92-3.99 ppm for 
2d, versus 3.82-3.94 ppm for 13b.  The alpha proton shows up as a doublet at 3.11 ppm 
with a coupling constant of 3.5 Hz for 2d, while the same doublet shows up at 3.25 ppm 
and has a coupling constant of 6.0 Hz for 13b.  Finally, the methyl group on the side 
chain of threonine shows up 1.24 ppm for 2d with a coupling constant of 6.2 Hz, versus 
1.19 ppm for 13b, with the same coupling constant.  It is clear that these two spectra are 
of the same compound, with very slight differences due to the spatial orientation of the 
groups that are attached to the two chiral centers in each molecule. 
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Scheme 2.14: Epimerization of Thr Due to 2-Step Benzylation Procedure.  The (L) 
and (D) isomers 2d and 13 were formed in a 2:1 ratio due to the acidity of the imine 
intermediate’s alpha proton. 
 
 
Our nitrosamine reduction procedure has several advantages, in that the starting 
materials are all cheap and readily available, and that it can be used to synthesize 
hydrazino amino acids from the corresponding amino acids without a loss of chirality at 
the α-carbon.  However, there are also some problems: the tert-butylnitrite reagent is 
toxic and carcinogenic, the highly acidic conditions limit the types of side chain groups 
and protecting groups that can be present, and there is a tendency to over-reduce the 
nitrosamine back to the parent amine rather than stopping at the hydrazine.  We had the 
most trouble with the synthesis of the benzyl lysine hydrazine 5b.  Although we were 
able to selectively protect, deprotect, and react each of the two amino groups of lysine, as 
well as form the nitrosamine 3b, we were not able to reduce 3b to the hydrazine 4b 
cleanly, as depicted in Scheme 2.15.  Rather, we obtained a multitude of decomposition 
products, as evidenced by TLC and proton NMR.     
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Figure 2.6: NMRs of N-Benzyl-(L)-Threonine Methyl Ester (top) and N-Benzyl-(D)-
Threonine Methyl Ester.  The two diastereomers could clearly be differentiated by 
proton NMR, as well as by TLC. 
N-Benzyl α-(L)-Threonine 
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Scheme 2.15: Unsuccessful Attempt to Reduce Lys Nitrosamine 3b.  Unlike the other 
amino acids we have reported, compound 3b gave a complex mixture of products upon 
repeated attempts to reduce it using Zn/HCl. 
 
 
This problem was solved by reacting lysine benzyl amine 2b with oxaziridine 10, 
as shown in Scheme 2.16, to directly form the desired benzyl lysine hydrazine 5b in good 
yield.  Oxaziridine 10 was synthesized in our lab following a literature procedure (20,34), 
and the yield and ease of using it to synthesize a Boc-protected hydrazine were an 
improvement over our own nitrosamine method.  10 also has the advantage of being 
much less carcinogenic and volatile compared with tert-butylnitrite.  However, the 
procedure to synthesize 10 is highly laborious and time-consuming, and it requires the 
use of chloral, which is a controlled substance in the United States that is not readily 
available for purchase from commercial sources. 
Unlike the nonpolar amino acids, the polar amino acids were not readily available 
as the hydrochloride salts of the methyl esters.  Thus, we obtained compounds 11c–e as 
the free acids with their amino groups protected by a Cbz.  11 was treated with potassium 
carbonate and methyl iodide to give methyl ester 12, which was then deprotected on the 
amine by hydrogenolysis to give starting material 1c–1e.   This series of protection and 
deprotection steps is depicted in Scheme 2.17. 
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Scheme 2.16: Procedure for Synthesizing Compound 6b (Lys).  The nitrosamine of 
Lys 5b could not be reduced to hydrazine 6b using Zn/HCl, but compound 6b was 
successfully synthesized using the Boc-protected oxaziridine 10 according to literature 
procedure (20,34).  The final hydrogenation step resulted in multiple products. 
 
 
 
 The lysine starting material 1b was also formed from the free acid, but a few 
additional steps were necessary in order to selectively protect the alpha and epsilon 
nitrogens.  We began with compound 11b, which was orthogonally protected by a Boc 
group on the alpha nitrogen and a Cbz group on the epsilon nitrogen.  This was reacted 
with methyl iodide and potassium carbonate to form methyl ester 12b as before.  The Cbz 
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group was then removed from the epsilon nitrogen by hydrogenolysis, and compound 7 
was immediately reacted with phthalic anhydride 8 to form the lysine phthalimide 9 in 
excellent yield.  Finally, the alpha nitrogen of 9 was deprotected using a 1:1 mixture of 
TFA and DCM to give starting material 1b.  This procedure is shown in Scheme 2.18. 
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Scheme 2.17: Synthesis of Ser, Thr, and Tyr Methyl Esters (1c-e).  The three tert-
butyl ether-protected alcohol side chain amino esters were synthesized from the 
commercially available Cbz-protected acids in high yield. 
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Scheme 2.18: Procedure for Synthesizing Compound 1b (Lys).  The amino group on 
the side chain of Lys was protected as a phthalimide in order to selectively form the 
hydrazine on the alpha amino group.  
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Scheme 2.19: Deprotection of Nonpolar Amino Acid Hydrazines.  Compounds 5f – 5i 
were synthesized as described previously by our group (21, 22).  Hydrogenolysis of the 
benzylated hydrazines gave compounds 6f - 6i. 
 
 
 
Finally, all of the benzyl-protected hydrazines that were synthesized previously 
by our group were deprotected via hydrogenolysis.  Previously, only the phenylalanine 
example had been attempted and published (21).  The procedure for synthesizing 6f–6i 
was analogous to that described for deprotection of the polar amino acid hydrazines 
above, and is shown in Scheme 2.19.  It was difficult to deprotect the methionine benzyl 
hydrazine 5i due to the sulfur poisoning the catalyst.  We attempted to overcome this 
problem by adding several drops of acetic acid, as well as by adding excess Pd/C.  The 
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use of excess Pd/C was more helpful than adding acetic acid, but even with this change to 
the procedure, the yield was still significantly lower than it was for the other amino acids.  
The final lysine compound 6b could not be obtained; repeated attempts to hydrogenate 
benzyl-protected hydrazine 5b gave either starting material or multiple decomposition 
products as evidenced by TLC and NMR. 
In conclusion, we have successfully deprotected the nonpolar hydrazino amino 
acids that were published by our group previously (21).  We have also synthesized the 
hydrazine derivatives of five additional amino acids using modified procedures.  Future 
work on this project will entail continued efforts to successfully deprotect the lysine 
benzyl hydrazine 5b, as well as the synthesis of the hydrazino amino acid derivatives of 
the remaining ten natural amino acids. 
2.3 Experimental Data 
 
N
O
O
OH
13a  
Experimental Procedure to Synthesize Methyl tert-Butoxy-N-Benzylidene-(R)-
Threoninate (13a).  A 100 mL Schlenk flask was placed in an ice bath with a stir bar and 
flushed with argon.  The methyl amino acid 1d (2.55 mmol) was dissolved in the flask in 
a few mL of anhydrous THF, and this mixture was stirred for ten minutes at 0 °C.  Then 
benzaldehyde (5.10 mmol) and TEA (2.55 mmol) were added, along with a small scoop 
of MgSO4 to keep the reaction dry.  The reaction was allowed to come to room 
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temperature and stirred overnight.  The MgSO4 was then removed by filtering the 
reaction mixture through a powder funnel and rinsing the MgSO4 several times with 
THF.  The crude product 13a was obtained by evaporating the THF under reduced 
pressure, and was carried on to the next step without purification due to the instability of 
the imine to column chromatography.  Rf  = 0.56 (3:1 hexanes/EtOAc); 1H NMR (250 
MHz, MeOD) δ 2.17 (s, 9H), 2.26 (d, J = 7.6 Hz, 1H), 2.39 (d, J = 6.3 Hz, 1H), 2.56 
(quin, J = 6.3 Hz), 2.75 (quin, J = 6.2 Hz, 1H), 3.33 (s, 3H), 5.83-5.91 (m, 3H), 6.22-6.25 
(m, 2H), 6.67 (s, 1H), 6.75 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 19.48, 20.44, 28.54, 
28.72, 52.21, 69.26, 75.42, 80.13, 80.90, 129.44, 132.10, 136.60, 166.58, 166.77, 172.68 
(The peak intensities were approximately the same for the both isomers, so the signals 
reported are for both isomers); ESI-MS (0.1% AcOH in MeOH) 278.1 (M+H)+. 
  
Experimental Procedure to Synthesize (S)- and (R)-Methyl tert-Butoxy-N-Benzyl-
Threoninate (2d and 13b).  Compound 13a (2.55 mmol) was dissolved in several mL of 
dry MeOH, flushed with argon, and stirred at room temperature.  Sodium borohydride 
(10.20 mmol) was added slowly in three portions over the course of ten minutes due to 
vigorous bubbling in the reaction.  The reaction was stirred at room temperature for two 
hours, and then worked up with 1M NaOH.  This was extracted three times with ethyl 
acetate, and the three organic layers were combined and washed with brine, dried over 
MgSO4, and evaporated under reduced pressure to give the benzyl amines 13b and 2d.  
The crude products were chromatographed in 9:1 hexanes/ethyl acetate to give the pure 
products in a 2:1 (S):(R) ratio in an overall yield of 54.5%. 
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2d  
Methyl tert-Butoxy-N-Benzyl-(S)-Threoninate (2d).  Rf  = 0.56 (3:1 hexanes/EtOAc); 
1H NMR (250 MHz, CDCl3) δ 1.12 (s, 9H), 1.24 (d, J = 6.2 Hz, 3H), 2.23 (broad, 1H), 
3.12 (d, J = 3.5 Hz, 1H), 3.57-3.62 (m, 1H), 3.70 (s, 3H), 3.92-3.99 (m, 2H), 7.22-7.38 
(m, 5H); 13C NMR (75 MHz, CDCl3) δ 20.57, 28.29, 51.52, 52.08, 65.87, 68.50, 73.65, 
126.85, 128.20, 128.27, 140.09, 174.17; ESI-MS (0.1% AcOH in MeOH) 280.1 (M+H)+. 
 
13b
N
O
H O
O
 
Methyl tert-Butoxy-N-Benzyl-(R)-Threoninate (13b).  Rf = 0.44 (3:1 hexanes/ 
EtOAc); 1H NMR (250 MHz, CDCl3) δ 1.13 (s, 9H), 1.19 (d, J = 6.2 Hz, 3H), 2.36 
(broad, 1H), 3.24 (d, J = 5.8 Hz, 1H), 3.64-3.67 (m, 1H), 3.73 (s, 3H), 3.84 (quin, J = 5.2 
Hz, 1H), 3.90-3.94 (m, 1H), 7.24-7.26 (m, 1H), 7.31-7.35 (m, 4H); 13C NMR (100 MHz, 
CDCl3) δ 19.83, 28.56, 51.79, 52.45, 66.38, 69.02, 74.31, 127.22, 128.50, 128.55, 139.80, 
174.47; ESI-MS (0.1% AcOH in MeOH) 280.1 (M+H)+. 
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Experimental Procedure for Reductive Amination (2a-e).  The commercially 
available HCl salt of the alanine methyl ester 1a (10.7 mmol) or the previously 
synthesized methyl ester 1b-e was dissolved in dry MeOH (50 mL), and cooled to 0 °C.  
TEA (10.7 mmol) was added, followed by benzaldehyde (21.5 mmol).  The reaction was 
allowed to come to room temperature and stirred for 20 minutes.  Sodium 
cyanoborohydride (43.0 mmol) was then added to the reaction, which was stirred 
overnight.  The reaction mixture was quenched with 1M NaOH (30 mL), saturated with 
NaCl, and extracted three times with ethyl acetate.  Then, the combined ethyl acetate 
layers were extracted with saturated NaCl solution, dried over MgSO4, and evaporated 
under reduced pressure.  The pure product 2a-e was isolated by column chromatography 
(4:1 hexanes:ethyl acetate) in 40-90% yield.   
 
2a
NH
O
OCH3
 
Methyl N-Benzyl-(S)-Alaninate (2a).  Rf  = 0.31 (3:1 hexanes/EtOAc); 1H NMR (400 
MHz, CDCl3) δ 1.69 (d, J=7.2 Hz, 3H), 3.69-3.67 (m, 1H), 3.78 (s, 3H), 4.16 (d, J=12.8 
Hz, 1H), 4.25 (d, J=12.8 Hz, 1H), 7.40-7.35 (m, 3H), 7.64-7.62 (m, 2H); 13C NMR (100 
MHz, CDCl3) δ 15.08, 48.92, 53.13, 53.30, 129.16, 129.61, 129.74, 130.86, 169.06; ESI-
MS (0.1% AcOH in MeOH) 194.1 (M+H)+. 
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MeOH
TEA
N
OH
H O
N OO
H
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N
OBoc
H O
N OO
1b 2b
TFA
DCM
 
Methyl N’-Phthalyl-N-Benzyl-(S)-Lysinate (2b) via Methyl N’-Phthalyl-(S)-
Lysinate (1b).  Boc-protected amine 9 (0.383 mmol) was dissolved in a large excess of 
1:1 DCM/TFA.  The reaction mixture was stirred under argon at room temperature for 
ten minutes, and then the DCM/TFA was removed under reduced pressure to give crude 
1b as the trifluoroacetate salt.  1b was immediately carried on as described above to give 
2b in 66.7% yield. Rf  = 0.13 (3:1 hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) δ 1.36-
1.44 (m, 2H), 1.60-1.65 (m, 4H), 1.89 (broad, 1H), 3.22 (t, J = 6.8 Hz, 1H), 3.56-3.70 (m, 
6H), 3.73-3.78 (m, 1H), 7.18-7.26 (m, 5H), 7.66 (dd, J = 5.4 Hz, 2.8 Hz, 2H), 7.79 (dd, J 
= 5.4 Hz, 2.8 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 23.29, 28.47, 33.15, 37.89, 51.90, 
52.32, 60.62, 123.36, 123.38, 127.23, 128.42, 128.55, 128.57, 132.33, 134.08, 139.98, 
168.55, 176.02; HR ESI-MS (0.1% AcOH in MeOH) 381.18056 (M + H)+ 
 
N
O
H O
O
2c
 
Methyl tert-Butoxy-N-Benzyl-(S)-Serinate (2c). Rf  = 0.43 (3:1 hexanes/EtOAc); 1H 
NMR (250 MHz, CDCl3) δ 1.15 (s, 9H), 2.23 (broad, 1H), 3.43-3.47 (m, 1H), 3.58-3.62 
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(m, 2H), 3.70-3.75 (m, 1H), 3.73 (s, 3H), 3.89-3.95 (m, 1H), 7.24-7.37 (m, 5H); 13C 
NMR (75 MHz, CDCl3) δ 27.31, 51.65, 51.93, 61.00, 63.11, 73.14, 126.96, 128.25, 
128.31, 139.76, 173.82; HR ESI-MS (0.1% AcOH in MeOH) 266.17505 (M+H)+. 
 
N
O
H O
O
2d  
Methyl tert-Butoxy-N-Benzyl-(S)-Threoninate (2d). Rf  = 0.61 (3:1 hexanes/EtOAc); 
1H NMR (250 MHz, CDCl3) δ 1.13 (s, 9H), 1.24 (d, J = 6.2 Hz, 3H), 2.16 (broad, 1H), 
3.12 (d, J = 3.6 Hz, 1H), 3.58-3.63 (m, 1H), 3.72 (s, 3H), 3.92-3.99 (m, 2H), 7.23-7.38 
(m, 5H); 13C NMR (75 MHz, CDCl3) δ 20.51, 28.31, 51.49, 52.13, 66.01, 68.53, 73.66, 
126.83, 128.19, 128.26, 140.13, 174.19; ESI-MS (0.1% AcOH in MeOH) 280.2 (M+H)+. 
 
N
O
H O
O
2e  
Methyl tert-Butoxy-N-Benzyl-(S)-Tyrosinate (2e).  Rf  = 0.46 (3:1 hexanes/EtOAc); 
1H NMR (250 MHz, CDCl3) δ 1.35 (s, 9H), 1.96 (broad, 1H), 2.93 (d, J = 7.0 Hz, 2 H), 
3.52 (t, J = 7.0 Hz, 1H), 3.61-3.66 (m, 1H), 3.63 (s, 3H), 4.70 (s, 2H), 6.92 (d, J = 8.4 Hz, 
2H), 7.07 (d, J = 8.4 Hz, 2H), 7.20-7.39 (m, 5H); 13C NMR (75 MHz, CDCl3) δ 28.80, 
39.10, 51.64, 51.93, 62.09, 65.23, 78.36, 124.21, 126.95, 127.02, 127.58, 128.09, 128.33, 
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128.52, 129.59, 132.17, 139.46, 153.94, 175.17; HR ESI-MS (0.1% AcOH in MeOH) 
342.20687 (M+H)+. 
 
Experimental Procedure for Nitrosamine Formation (3a-e).  The benzyl protected 
amine 2 (1.14 mmol) was dissolved in DCM (10 mL), cooled to 0 °C, and tert-
butylnitrite (1.25 mmol) in DCM was added drop-wise from an addition funnel.  The 
reaction was refluxed for 4 hours, cooled to RT, and stirred overnight.  The solvent was 
evaporated under reduced pressure to give nitrosamine 3 as yellow oil in a 100 % yield.  
Nitrosamines were typically pure and did not require chromatography. 
 
N
O
N O
O
3a  
Methyl N-Benzyl-N-Nitroso-(S)-Alaninate (3a).  Rf  = 0.33 (3:1 hexanes/EtOAc); 1H 
NMR (400 MHz, CDCl3) δ 1.69 (d, J = 7.2 Hz, 3H), 2.48 (d, J = 6.8 Hz, 3H), 3.57 (s, 
3H), 3.67 (s, 3H), 4.54 (q, J = 7.6 Hz, 1H), 4.72 (d, J = 15.2 Hz, 1H), 4.94 (d, J = 15.2 
Hz, 1H), 5.21 (q, J = 7.6 Hz, 1H), 5.39 (s, 2H), 7.08-7.09 (m, 2H), 7.27-7.30 (m, 3H), 
7.37-7.39 (m, 5H); 13C NMR (100 MHz, CDCl3) δ 13.14, 16.47, 46.64, 52.35, 52.72, 
52.96, 55.42, 59.96, 127.78, 127.98, 128.40, 128.61, 128.73, 128.91, 134.32, 134.61, 
168.94, 170.87 (The peak intensities were approximately the same for the both isomers, 
so the signals reported are for both isomers); ESI-MS (0.1% AcOH in MeOH) 223.1 
(M+H)+. 
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Methyl N’-Phthalyl-N-Benzyl-N-Nitroso-(S)-Lysinate (3b).  Rf  = 0.09, 0.15 (3:1 
hexanes/EtOAc; two nitrosamine stereoisomers); 1H NMR (400 MHz, CDCl3) δ 1.17-
1.29 (m, 2H), 1.44-1.60 (m, 2H), 2.09-2.24 (m, 2H), 3.46 (s, 3H), 3.47-3.62 (m, 2H), 
4.64-4.74 (m, 1H), 4.90-5.03 (m, 1H), 5.28-5.38 (m, 1H), 7.03-7.10 (m, 1H), 7.20-7.42 
(m, 4H), 7.71-7.73 (m, 2H), 7.82-7.83 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 23.42, 
28.02, 28.14, 29.50, 37.48, 46.94, 52.38, 52.80, 55.66, 56.15, 64.65, 123.37, 128.06, 
128.16, 128.67, 128.80, 128.85, 128.94, 129.01, 129.84, 132.21, 134.16, 134.20, 134.48, 
168.44, 170.40; (The spectrum is complex as with all of the nitrosamines; several of the 
peaks split for both proton and carbon NMRs.  No MS was taken of this compound due to 
its toxicity and carcinogenicity.) 
 
N
O
N O
O
O
3c  
Methyl tert-Butoxy-N-Benzyl-N-Nitroso-(S)-Serinate (3c). Rf = 0.43, 0.48 (3:1 
hexanes/ EtOAc; two nitrosamine stereoisomers); 1H NMR (250 MHz, CDCl3) δ 1.05 (s, 
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9H), 1.10 (s, 9H), 3.58 (s, 3H), 3.71 (s, 3H), 3.73-3.77 (m, 2H), 3.92 (dd, J = 4.1 Hz, 9.7 
Hz, 1H), 4.00-4.07 (m, 1H), 4.45-4.50 (m, 1H), 4.75-4.81 (m, 1H), 5.05-5.11 (m, 1H), 
5.20-5.26 (m, 1H), 5.34-5.39 (m, 1H), 5.74-5.80 (m, 1H), 7.09-7.11 (m, 1H), 7.26-7.28 
(m, 2H), 7.36-7.40 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 26.98, 27.19, 47.91, 52.08, 
52.50, 56.87, 58.65, 60.84, 65.07, 73.80, 127.27, 127.64, 128.32, 128.65, 134.71, 168.88 
(The peak intensities were approximately the same for the both isomers, so the signals 
reported are for both isomers. No MS was taken of this compound due to its toxicity and 
carcinogenicity.) 
 
N
O
N O
O
O
3d  
Methyl tert-Butoxy-N-Benzyl-N-Nitroso-(S)-Threoninate (3d).  Rf  = 0.37, 0.44 (3:1 
hexanes/EtOAc; two nitrosamine stereoisomers); 1H NMR (250 MHz, CDCl3) δ 1.15 (s, 
9H), 1.16 (d, J = 6.2 Hz, 3H), 1.20 (s, 9H), 3.50 (s, 3H), 3.64 (s, 3H), 4.35-4.36 (m, 1H), 
4.53-4.58 (m, 1H), 4.75-4.81 (m, 1H), 5.14-5.25 (m, 2H), 5.79-5.85 (m, 1H), 7.17-7.47 
(m, 5H); 13C NMR (75 MHz, CDCl3) δ 20.88, 22.01, 28.55, 28.69, 49.52, 51.84, 52.27, 
57.53, 61.59, 66.05, 68.16, 70.41, 74.81, 127.13, 128.21, 128.40, 129.31, 134.73, 135.04, 
168.82 (The peak intensities were approximately in a 2:1 ratio for the two isomers, so the 
signals are reported for both isomers.  No MS was taken of this compound due to its 
toxicity and carcinogenicity.) 
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Methyl tert-Butoxy-N-Benzyl-N-Nitroso-(S)-Tyrosinate (3e).  Rf = 0.45 (3:1 
hexanes/EtOAc); 1H NMR (250 MHz, CDCl3) δ 1.32 (s, 9H), 1.35 (s, 9H), 3.01-3.06 (m, 
1H), 3.24-3.29 (m, 2H), 3.40-3.49 (m, 2H), 3.51 (s, 3H), 3.62 (s, 3H), 4.15-4.23 (m, 3H), 
4.52-4.82 (m, 4H), 4.80-4.84 (m, 1H), 5.40-5.46 (m, 1H), 6.85 (d, J = 8.2 Hz, 2H), 6.95 
(d, J = 8.4 Hz, 2H), 7.16-7.22 (m, 5H), 7.30-7.36 (m, 5H); 13C NMR (75 MHz, CDCl3) δ 
28.78, 32.63, 35.86, 47.60, 52.22, 52.70, 56.98, 59.60, 65.11, 65.37, 78.58, 124.29, 
124.61, 126.90, 127.45, 127.78, 128.38, 128.60, 128.68, 129.10, 129.54, 130.74, 131.61, 
133.28, 133.50, 154.32, 167.59, 169.80 (The peak intensities were approximately the 
same for the both isomers, so the signals reported are for both isomers. No MS was taken 
of this compound due to its toxicity and carcinogenicity.) 
 
 Experimental Procedure for Boc-Protected α-Hydrazino Esters via Hydrazine 
Formation (5a-e).  Zinc was activated by washing with 10% HCl, dI water, methanol, 
and diethyl ether.  The nitrosamine 3 (1.60 mmol) was dissolved in dry MeOH (15 mL) 
under argon in a 3-necked flask.  A powder addition funnel was filled with activated Zn 
(12.8 mmol) and fitted to one neck, while the other two necks were sealed with rubber 
septa.  The reaction system was then cooled to -78 °C, and activated Zn was slowly 
added to the stirred suspension, followed by addition of conc. HCl (12.8 mmol) via 
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syringe.  The reaction was then stirred under argon at -78 °C for 4 hours.  To work up the 
reaction, the excess Zn was filtered while the reaction mixture was still cold, and the 
filtrate was treated with cold 6N KOH until it was strongly basic (pH 12-13).  It was then 
extracted with 3 equal portions of cold ethyl acetate.  The combined ethyl acetate layers 
were dried over Na2SO4, and evaporated under reduced pressure from a RT water bath, to 
give the hydrazine.  The neat oil will oligomerize, so the hydrazines were immediately 
protected using Boc anhydride with no characterization.  Melted tert-Boc2O (4.32 mmol) 
was added directly to 4 (3.92 mmol) and they were stirred together for 30 min at room 
temperature neat.  After 30 min, a very small amount of acetonitrile was added to prevent 
the reaction from solidifying, and the reaction mixture was stirred overnight.  The 
acetonitrile was removed under reduced pressure at RT, and the product 5 was isolated by 
column chromatography (4:1 hexanes:ethyl acetate) in 38-100% yield. 
 
N
O
N O
H Boc
5a  
Methyl N-Amino-N-Benzyl-N’-tert-butoxycarbonyl-(S)-Alaninate (5a).  Rf  = 0.45 
(3:1 hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) δ 1.32-1.44 (m, 12H), 3.62-3.64 (m, 
1H), 3.71 (s, 3H), 3.95-4.05 (m, 2H), 6.60 (broad, 1H), 7.24-7.30 (m, 3H), 7.31-7.40 (m, 
2H); 13C NMR (100 MHz, CDCl3) δ 16.21, 28.19, 51.55, 60.08, 60.65, 79.52, 127.41, 
128.20, 129.27, 136.89, 155.37, 175.50; HR ESI-MS (0.1% AcOH in MeOH) 331.18090 
(M + H)+ 
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Methyl N’-Phthalyl-N-Amino-N-Benzyl-N’’-tert-Butoxycarbonyl-(S)-Lysinate (5b).  
Rf  = 0.29 (3:1 hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) δ 1.33 (s, 9H), 1.56-1.60 
(m, 2H), 1.70-1.78 (m, 4H), 3.35-3.39 (m, 1H), 3.63-3.65 (m, 2H), 3.88-3.91 (m, 1H), 
3.98-4.00 (m, 1H), 6.70 (broad, 1H), 7.20-7.37 (m, 5H), 7.70 (d, J = 2.8 Hz, 2H), 7.82 (d, 
J = 2.8 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 23.59, 28.33, 29.86, 37.96, 51.81, 61.32, 
64.23, 79.94, 95.90, 123.37, 127.74, 128.46, 129.65, 130.09, 132.41, 134.05, 136.89, 
155.37, 168.62, 174.38; HR ESI-MS (0.1% AcOH in MeOH) 496.24433 (M + H)+  
 
N
O
N O
H Boc
O
5c  
Methyl tert-Butoxy-N-Amino-N-Benzyl-N’-tert-Butoxycarbonyl-(S)-Serinate (5c). 
Rf  = 0.40 (3:1 hexanes/EtOAc); 1H NMR (250 MHz, CDCl3) δ 1.12 (s, 9H), 1.36 (s, 9H), 
3.65-3.81 (m, 3H), 3.73 (s, 3H), 3.94-4.04 (m, 2H), 6.69 (broad, 1H), 7.23-7.31 (m, 3H), 
7.39-7.41 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 27.25, 27.37, 27.47, 27.54, 28.47, 
51.68, 61.24, 61.88, 65.33, 65.71, 73.47, 79.80, 127.65, 128.39, 128.59, 129.29, 129.60, 
137.00, 172.49; HR ESI-MS (0.1% AcOH in MeOH) 403.22016 (M + Na)+ 
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5d  
Methyl tert-Butoxy-N-Amino-N-Benzyl-N’-tert-Butoxycarbonyl-(S)-Threoninate (5d).  Rf  
= 0.54 (3:1 hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) δ 1.10 (s, 9H), 1.27 (d, J = 6.3 
Hz), 1.38 (s, 9H), 3.44-3.45 (m, 1H), 3.72 (s, 3H), 3.92-3.98 (m, 1H), 4.17-4.22 (m, 2H), 
6.94 (broad, 1H), 7.22-7.42 (m, 5H); 13C NMR (100 MHz, CDCl3) δ 20.24, 28.32, 51.30, 
61.62, 68.63, 69.93, 73.74, 79.10, 127.25, 128.09, 129.17, 137.49, 155.05, 172.37; HR 
ESI-MS (0.1% AcOH in MeOH) 395.25477 (M + H)+ 
 
N
O
N O
O
BocH
5e
 
Methyl tert-Butoxy-N-Amino-N-Benzyl-N’-tert-Butoxycarbonyl-(S)-Tyrosinate (5e).  Rf  = 
0.46 (3:1 hexanes/EtOAc); 1H NMR (250 MHz, CDCl3) δ 1.34 (s, 9H), 1.38 (s, 1H), 
2.89-3.01 (m, 1H), 3.06-3.12 (m, 1H), 3.62 (s, 3H), 3.67-3.71 (m, 1H), 3.92-3.99 (m, 
2H), 6.64 (broad, 1H), 6.90 (d, J  = 8.4 Hz, 2H), 7.14 (d, J = 8.4 Hz, 2H), 7.22-7.29 (m, 
5H); 13C NMR (75 MHz, CDCl3) δ 28.18, 28.80, 35.55, 51.37, 66.73, 78.13, 79.76, 
107.88, 123.93, 127.41, 128.08, 129.30, 129.66, 132.73, 136.47, 147.68, 151.93, 152.90, 
153.81, 173.38; HR ESI-MS (0.1% AcOH in MeOH) 479.25147 (M + Na)+ 
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General Procedure for Hydrogenolysis of Boc-Protected α-Hydrazino Esters (6a-
i). Compound 5 (1.32 mmol) was dissolved in MeOH (8 mL) and 10% Pd/C (0.280 g) 
was added.  The solution was hydrogenated at 45 psi H2 in a Paar Hydrogenator for 3 
hours.  The reaction mixture was filtered through a Celite cake, which was rinsed with 
MeOH.  Evaporation of the MeOH yielded 6 in 67-100% yield.  
 
N
OH
N O
BocH
6a  
Methyl N-Amino-N’-tert-Butoxycarbonyl-(S)-Alaninate (6a).  Rf  = 0.15 (3:1 
hexanes/ EtOAc); 1H NMR (400 MHz, CDCl3) δ 1.33 (d, J = 7.2 Hz, 3H), 1.45 (s, 9H), 
3.71-3.75 (m, 4H), 4.17 (broad, 1H), 6.34 (broad, 1H); 13C NMR (100 MHz, CDCl3) δ 
16.00, 28.30, 52.11, 58.47, 80.68, 156.36, 174.30; HR ESI-MS (0.1% AcOH in MeOH) 
241.11595 (M + Na)+ 
 
N
OH
N O
BocH
O
6c  
Methyl tert-Butoxy-N-Amino -N’-tert-Butoxycarbonyl-(S)-Serinate (6c). Rf  = 0.36 
(3:1 hexanes/EtOAc); 1H NMR (250 MHz, CDCl3) δ 1.14 (s, 9H), 1.44 (s, 9H), 2.69 
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(broad, 1H), 3.68-3.73 (m, 2H), 3.75 (s, 3H), 6.39 (broad, 1H), 6.64 (broad, 1H); 13C 
NMR (100 MHz, CDCl3) δ 27.45, 28.52, 44.23, 51.66, 52.21, 61.47, 63.88, 68.01, 73.51, 
73.62, 80.60, 156.25, 172.19; HR ESI-MS (0.1% AcOH in MeOH) 313.17306 (M + Na)+ 
 
N
OH
N O
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6d  
Methyl tert-Butoxy-N-Amino- N’-tert-Butoxycarbonyl-(S)-Threoninate (6d).  Rf  = 
0.20 (3:1 hexanes/EtOAc); 1H NMR (250 MHz, CDCl3) δ 1.10 (s, 9H), 1.30 (d, J = 6.2 
Hz, 3H), 1.42 (s, 9H), 3.43 (broad, 1H), 3.72 (s, 3H), 3.98-4.02 (m, 1H), 6.22 (broad, 
1H); 13C NMR (75 MHz, CDCl3) δ 20.64, 28.26, 51.85, 67.49, 69.38, 73.87, 80.12, 
155.93, 172.84; HR ESI-MS (0.1% AcOH in MeOH) 327.18926 (M + Na)+ 
 
N
OH
N O
O
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6e
 
Methyl tert-Butoxy-N-Amino -N’-tert-Butoxycarbonyl-(S)-Tyrosinate (6e).  MP = 
48-49 °C; Rf  = 0.39 (3:1 hexanes/EtOAc); 1H NMR (250 MHz, CDCl3) δ 1.32 (s, 9H), 
1.41 (s, 9H), 2.93-3.04 (m, 2H), 3.67 (s, 3H), 3.91 (t, J = 6.6 Hz, 1H), 4.18 (broad, 1H), 
6.18 (broad, 1H), 6.91 (d, J= 8.4 Hz, 2H), 7.10 (d, J = 8.4 Hz, 2H); 13C NMR (75 MHz, 
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CDCl3) δ 28.22, 28.77, 36.42, 51.93, 64.25, 80.60, 124.23, 129.53, 131.17, 154.18, 
156.08, 173.15; HR ESI-MS (0.1% AcOH in MeOH) 389.20463 (M + Na)+ 
 
N
OH
N O
BocH
6f  
Methyl N-Amino-N’-tert-Butoxycarbonyl-(S)-Valinate (6f). Rf = 0.28 (3:1 hexanes/ 
EtOAc); 1H NMR (250 MHz, CDCl3) δ 0.97-1.02 (m, 6H), 1.44 (s, 9H), 2.01-2.06 (m, 1 
H), 3.48 (d, J = 4.4 Hz, 1 H), 3.75 (s, 3H), 4.17 (broad, 1H), 6.19 (broad, 1H); 13C NMR 
(75 MHz, CDCl3) δ 18.93, 19.40, 28.69, 30.34, 52.30, 69.74, 81.09, 156.70, 173.95; HR 
ESI-MS (0.1% AcOH in MeOH) 269.14784 (M + Na)+  
 
N
OH
N O
BocH
6g  
Methyl N-Amino-N’-tert-Butoxycarbonyl-(S)-Isoleucinate (6g). Rf = 0.37 (3:1 
hexanes/EtOAc); 1H NMR (250 MHz, CDCl3) δ 0.76-0.86 (m, 6H), 1.13-1.18 (m, 1H), 
1.32 (s, 9H), 1.37-1.44 (m, 1H), 1.66-1.68 (m, 1H), 3.41 (d, J = 4.9 Hz, 1H), 3.62 (s, 3H), 
4.09 (broad, 1H), 6.48 (broad, 1H); 13C NMR (75 MHz, CDCl3) δ 11.86, 12.09, 15.18, 
15.77, 25.95, 26.43, 28.52, 34.86, 36.97, 51.90, 52.05, 67.80, 68.46, 80.52, 156.73, 
173.80, 174.20; HR ESI-MS (0.1% AcOH in MeOH) 283.16317 (M + Na)+ 
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N
OH
N O
BocH
6h  
Methyl N-Amino-N’-tert-Butoxycarbonyl-(S)-Leucinate (6h). Rf = 0.40 (3:1 
hexanes/EtOAc); 1H NMR (250 MHz, CDCl3) δ 0.85 (d, J = 7.3 Hz, 6H), 1.35 (s, 9H), 
1.38-1.44 (m, 1H), 1.69-1.75 (m, 1H), 3.57 (m, 1H), 3.64 (s, 3H), 4.08 (broad, 1H), 6.48 
(broad, 1H); 13C NMR (75 MHz, CDCl3) δ 22.44, 23.24, 25.22, 28.64, 39.99, 52.36, 
62.26, 80.79, 156.64, 174.95; HR ESI-MS (0.1% AcOH in MeOH) 283.16326 (M + Na)+ 
 
N
OH
N O
BocH
S6i  
 
Methyl N-Amino-N’-tert-Butoxycarbonyl-(S)-Methioninate (6i).  Rf = 0.14 (3:1 
hexanes/EtOAc); 1H NMR (250 MHz, CDCl3) δ 1.44 (s, 9H), 2.00-2.08 (m, 2H), 2.09 (s, 
3H), 2.65 (t, J = 7.8 Hz, 2H,) 3.68-3.72 (m, 1H), 3.75 (s, 3H), 4.25 (broad, 1H), 6.25 
(broad, 1H); 13C NMR (125 MHz, CDCl3) δ 15.64, 28.49, 30.06, 30.58, 52.45, 62.42, 
80.93, 156.51, 173.79; HR ESI-MS (0.1% AcOH in MeOH) 301.12002 (M + Na)+   
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Experimental Procedure to Synthesize Methyl N’-Phthalyl-N-tert-Butoxycarbonyl-
(S)-Lysinate (9).  Compound 12b (2.54 mmol) was dissolved in ~10 mL methanol, to 
which was added a few drops of glacial AcOH and 0.1 g 10% Pd/C.  The mixture was 
shaken under H2 at 50 psi for one hour, filtered through a Celite cake to remove the Pd/C, 
and evaporated under reduced pressure to give the free amine 7.  Deprotected amine 7 
(2.54 mmol) was immediately dissolved in 20 mL dry dioxane in a three-necked flask.  
Phthalic anhydride 8 (2.80 mmol) and TEA (2.80 mmol) were added, the reaction was 
fitted with a condenser and drying tube, and it was then refluxed overnight.  The reaction 
was cooled after 16 hours and diluted with EtOAc.  Then the organic layer was washed 
with dI water (3x) and brine (2x), dried over MgSO4, and evaporated under reduced 
pressure.  The pure product 9 was isolated in 100% yield with no purification needed.  Rf  
= 0.15 (3:1 hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) δ 1.43-1.44 (m, 11H), 1.65-
1.72 (m, 3H), 1.82-1.85 (m, 1H), 3.66-3.70 (m, 2H), 3.73 (s, 3H), 4.28-4.29 (m, 1H), 5.08 
(broad, 1H), 7.72 (dd, J = 5.4 Hz, 3.2 Hz, 2H), 7.84 (dd, J = 5.2 Hz, 3.2 Hz, 2H); 13C 
NMR (100 MHz, CDCl3) δ 22.75, 28.28, 28.48, 32.34, 37.66, 52.44, 53.42, 67.25, 80.01, 
123.39, 132.28, 134.07, 155.56, 168.57, 173.41; HR ESI-MS (0.1% AcOH in MeOH) 
413.16832 (M + Na)+ 
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Experimental Procedure for Methyl Esterification (12b-12e).  The commercially 
available amino acid 11b-11e (3.49 mmol) was dissolved in dry DMF (20 mL) and 
cooled to 0 °C.  Anhydrous potassium carbonate (3.84 mmol) was added, and the reaction 
was flushed with argon and stirred at 0 °C for 10 minutes.  Methyl iodide (6.98 mmol) 
was then added drop-wise via syringe, and the reaction was allowed to warm up to room 
temperature.  After stirring for 4.5 hours, the reaction was diluted with ethyl acetate (50 
mL) and washed twice with saturated sodium bicarbonate solution.  The organic layer 
was then washed once with saturated NaCl solution, dried over MgSO4, and evaporated 
under reduced pressure.  The pure product 12c-12e was isolated by filtering through a 
small pad of silica using 3:1 hexanes:ethyl acetate in 91-100% yield. 
 
12b
N
OBoc
H O
N
H Cbz
 
Methyl N-tert-Butoxycarbonyl-N’-Carboxybenzyl-(S)-Lysinate (12b).  Rf  = 0.29 
(3:1 hexane/EtOAc); 1H NMR (400 MHz, CDCl3) δ 1.36-1.41 (m, 2H), 1.43 (s, 9H), 
1.49-1.56 (m, 2H), 1.60-1.64 (m, 1H), 1.76-1.83 (m, 1H), 3.16-3.21 (m, 2H), 3.73 (s, 
3H), 4.24-4.29 (m, 1H), 4.87 (broad, 1H), 5.09 (s, 2H), 5.12 (broad, 1H), 7.31-7.36 (m, 
5H); 13C NMR (100 MHz, CDCl3) δ 14.41, 22.61, 28.52, 29.59, 30.54, 32.58, 40.84, 
52.49, 53.38, 66.85, 80.14, 128.31, 128.34, 128.72, 136.83, 156.70, 171.36, 173.48; ESI-
MS (0.1% AcOH in MeOH) 417.1 (M + Na)+ 
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O
12c  
Methyl tert-Butoxy-N-Carboxybenzyl-(S)-Serinate (12c).  Rf = 0.35 (3:1 hexanes/ 
EtOAc); 1H NMR (250 MHz, CDCl3) δ 1.12 (s, 9H), 3.57 (dd, J = 3.1 Hz, 9.0 Hz, 1H), 
3.74 (s, 3H), 3.81 (dd, J = 2.9 Hz, 9.1 Hz, 1H), 4.45-4.49 (m, 1H), 5.13 (s, 2H), 5.68 (d, J 
= 8.8 Hz, 1H), 7.31-7.37 (m, 5H); 13C NMR (75 MHz, CDCl3) δ 27.21, 52.33, 54.59, 
61.94, 66.94, 73.38, 128.12, 128.49, 136.25, 156.11, 171.11; HR ESI-MS (0.1% AcOH in 
MeOH) 310.16486 (M + H)+ 
 
N
OZ
H O
O
12d  
Methyl tert-Butoxy-N-Carboxybenzyl-(S)-Threoninate (12d).  Rf = 0.48 (3:1 
hexanes/EtOAc); 1H NMR (250 MHz, CDCl3) δ 1.10 (s, 9 H), 1.22 (d, J = 6.3 Hz, 3H), 
3.72 (s, 3H), 4.22-4.26 (m, 2H), 5.14 (s, 2H), 5.60 (d, J = 9.6 Hz, 1H), 7.32-7.41 (m, 5H); 
13C NMR (75 MHz, CDCl3) δ 21.00, 28.24, 52.20, 59.80, 67.01, 67.28, 74.00, 128.13, 
128.52, 136.25, 156.76, 171.61; HR ESI-MS (0.1% AcOH in MeOH) 346.16278 (M + 
Na)+ 
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Methyl tert-Butoxy-N-Carboxybenzyl-(S)-Tyrosinate (12e). Rf = 0.36 (3:1 hexanes/ 
EtOAc); 1H NMR (250 MHz, CDCl3) δ 1.33 (s, 9H), 3.07 (d, J = 5.9 Hz, 2H), 3.70 (s, 
3H), 4.64 (q, J  = 8.1 Hz, 1H), 5.10 (s, 2H), 5.28 (d, J = 8.2 Hz, 1H), 6.90 (d, J = 8.4 Hz, 
2H), 7.00 (d, J = 8.5 Hz, 2H), 7.32-7.35 (m, 5H); 13C NMR (75 MHz, CDCl3) δ 28.79, 
37.56, 52.26, 54.83, 66.94, 78.43, 124.25, 128.11, 128.19, 128.52, 129.67, 130.43, 
136.16, 154.39, 155.58, 172.02; HR ESI-MS (0.1% AcOH in MeOH) 408.17881 (M + 
Na)+ 
 
Experimental Procedure for Cbz Deprotection (1c-1e).  The methyl ester 12c-12e 
(3.04 mmol) was dissolved in MeOH (10 mL), and the mixture was slightly acidified by 
adding 10 drops of glacial acetic acid.  Then 10% Pd/C (0.4 g) was added, and the 
reaction was placed under a H2 environment at 50 psi on a Paar hydrogenator.  After 
shaking for 1 hour, the product was filtered through a small pad of Celite and evaporated 
under reduced pressure.  No purification was necessary to obtain the pure product 1c-1e 
in 92-100% yield. 
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1c  
Methyl tert-Butoxy-(S)-Serinate (1c). Rf  = 0.10 (100% EtOAc); 1H NMR (250 MHz, 
CDCl3) δ 0.96 (s, 9H), 3.41-3.48 (m, 3H), 3.53 (s, 3H), 3.75 (broad, 2H); 13C NMR (75 
MHz, CDCl3) δ 27.09, 51.81, 54.47, 63.00, 72.91, 173.67; HR ESI-MS (0.1% AcOH in 
MeOH) 176.12745 (M+H)+. 
 
N
OH
H O
O
1d  
Methyl tert-Butoxy-(S)-Threoninate (1d).  Rf  = 0.16 (100% EtOAc); 1H NMR (250 
MHz, CDCl3) δ 1.11 (s, 9H), 1.22 (d, J = 6.2 Hz, 3H), 3.32-3.33 (m, 1H), 3.53 (broad, 
2H), 3.70 (s, 3H), 3.99-4.04 (m, 1H); 13C NMR (75 MHz, CDCl3) δ 20.82, 28.36, 51.93, 
60.08, 68.02, 73.72, 174.58; HR ESI-MS (0.1% AcOH in MeOH) 190.14360 (M+H)+. 
 
1e
N
OH
H O
O
 
 69
Methyl tert-Butoxy-(S)-Tyrosinate (1e).  Rf = 0.26 (100% EtOAc); 1H NMR (250 
MHz, CDCl3) δ 1.32 (s, 9H), 2.33 (broad, 2H), 2.80-2.88 (m, 1H), 3.04 (dd, J = 5.3 Hz, 
13.6 Hz, 1H), 3.70 (s, 3H), 3.72-3.75 (m, 1H), 6.92 (d, J = 8.4 Hz, 2H), 7.07 (d, J = 8.4 
Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 28.77, 40.25, 51.96, 55.63, 78.37, 124.27, 129.64, 
131.75, 154.16, 175.29; HR ESI-MS (0.1% AcOH in MeOH) 252.15986 (M+H)+. 
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CHAPTER THREE 
 
SYNTHESIS OF MDM2 INHIBITORS AND KEY STRUCTURAL UNITS 
 
 
3.1 Introduction 
 
3.1.1 The Hallmarks of Cancer 
 
Cancer is fundamentally a genetic disease (1).  Our current best understanding 
suggests that cancer arises from multiple genetic transformations, and that the 
development of normal cells into cancerous cells is a multi-step process (1).  While no 
one genetic transformation is likely to be sufficient to cause cancer, a combination of 
several such transformations has been experimentally and clinically observed to lead to 
tumorigenesis (1).  In contrast to normal cells, which have tightly controlled cell growth 
cycles, cancer cells have some defect in the regulation of their cell cycles that allows 
them to proliferate in an uncontrolled manner (1). 
 Although there are literally dozens of known types of cancers in various tissues, 
cancer cells tend to have several common characteristics that relate to their abnormal 
proliferative ability.  These include self-sufficiency in producing growth signals, lack of 
response to anti-growth signals, evasion of programmed cell death (apoptosis), no limit to 
cell reproduction, the induction of new blood vessels to support tumor growth 
(angiogenesis), and the ability to invade other tissues (metastasis) (1).  These six defining 
characteristics are thought to be present in most if not all cancers; there may be additional 
common factors such as senescence as well (1).   
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Figure 3.1: Cellular Pathways that Can Be Affected in Cancer Cells (1).  These 
pathways are involved in cellular growth and death.  Bax and p53 are both depicted on 
the right side of the drawing as components of the intrinsic apoptotic pathway. 
 
 
 
There are several pathways in cells that are involved with cellular growth and 
death (1).  An examination of Figure 3.1 emphasizes how complex and redundant these 
pathways are, as well as their inter-relatedness.  MDM2, which is an inhibitor of the pro-
apoptotic tumor suppressor gene p53, and Bax, which is a promoter of apoptosis, can 
both be located at the right-hand side of the figure.  These two proteins and many others 
involved with apoptosis are potential targets for disrupting protein-protein interactions in 
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order to promote apoptosis.  This chapter will describe the design and synthesis of three 
potential small-molecule inhibitors of MDM2, as well as three key structural components 
needed to synthesize inhibitory MDM2 α-helix mimics.  Chapter 4 will focus on the 
design and synthesis of an α-helix mimic that is intended to stabilize the active form of 
the Bax protein. 
3.1.2 Apoptosis and MDM2/p53 
 
The cells in a multicellular organism exist in a precarious balance between life 
and programmed cell death, or apoptosis.  Apoptosis is the process by which unwanted 
cells that have genetic abnormalities, physical damage, or parasitic infection can be 
removed from the body (2,3).  In normal cells, the decision to undergo apoptosis is 
governed by the relative levels of pro-apoptotic and anti-apoptotic proteins.  Abnormal 
expression of many of these proteins has been implicated in the transformation of normal 
cells into cancer cells, and in fact is a common characteristic of cancer cells (1,3). 
Apoptosis is a controlled process that is often contrasted to necrosis, where cells 
die off in an uncontrolled manner (2).  However, it is probably more correct to think of 
necrosis and apoptosis as two extremes on a continuum of types of cell death (2).  
Apoptosis can be recognized based on specific morphological features, including nuclear 
fragmentation, chromatin condensation, cell shrinkage, and “blebbing” of the cell 
membrane (4). 
Traditionally, apoptosis was considered as only being effected by a family of 
proteases called caspases, but there are also non-caspase dependent forms of controlled 
cell death known (2).  The caspases are activated by two primary pathways, which are 
illustrated in Figure 3.2.  The intrinsic pathway involves the mitochondria, while the 
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extrinsic pathway involves signaling via death receptors (3,4).  Intrinsic pathway 
apoptosis occurs due to the release of cytochrome c from the mitochondria following 
depolarization of the mitochondrial proton gradient (3,4).  The intrinsic pathway is 
discussed further in the Introduction section of Chapter Four. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: The Intrinsic (Mitochondrial) and Extrinsic (FAS) Pathways (3).  Both 
p53/MDM2 and Bax (discussed in Chapter 4) are members of the intrinsic pathway.  The 
members of this pathway function by either promoting or inhibiting cytochrome c release 
from the mitochondria. 
 
 
One method by which cells become cancerous is due to the abnormal expression 
of mutated oncogenes, which code for proteins that affect the cell cycle, or tumor 
suppression genes, which block cell cycle progression (1).  p53 is a tumor suppressor 
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protein that detects damage to a cell’s DNA and either prevents the cell from dividing 
until after the DNA has been repaired, or causes the cell to undergo apoptosis if the 
damage to the DNA is severe enough (1,3,5).  p53 is regulated by MDM2 or HDM2, 
which are oncogene proteins in mice and humans respectively (3).  The remainder of this 
Introduction will use the term MDM2 to refer to both proteins.   
MDM2 physically inhibits p53, and it also promotes the ubiquitination of p53; 
p53 ubiquitination leads to the degradation of p53 by the proteasome (3,5,6).  In normal 
cells, p53 is unstable and has a short half-life due to MDM2-mediated degradation (6).  
Prevention of the MDM2-p53 interaction lengthens p53’s half-life considerably, from 
minutes to hours (6). 
 
 
 
Figure 3.3: Regulation of p53 by MDM2 (7).  This drawing shows the auto-regulatory 
feedback loop between p53 and MDM2. 
 
 
Figure 3.3 is a schematic showing the regulation of p53 by MDM2 (7).  MDM2 
and p53 are tied together in an auto-regulatory feedback loop, where p53 stimulates the 
expression of MDM2, and MDM2 inhibits p53 (7).  However, the pathway is very 
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complex and involves multiple other proteins.  For example, one protein called ARF is 
responsible for inhibiting MDM2 (7).  There are also multiple splice variants of MDM2, 
as well as related proteins with similar functions such as MDMX (7).  MDMX and 
MDM2 are known to interact with each other, and this interaction is also important in the 
regulation of p53 (8). 
Since apoptosis pathways are abnormal in many cancer cells and are not abnormal 
in regular cells, it is theoretically possible to develop pro-apoptotic drugs that selectively 
target cancer cells (1,3).  For example, it is estimated that up to half of human cancers 
have a disrupted or mutated p53 pathway, making p53 and its protein-protein interactions 
an important target of anti-cancer chemotherapy (3).   
Although p53 itself can be under-expressed due to mutation, its turnover can also 
be increased due to abnormally high levels of MDM2 (3,4).  For this reason, inhibitors of 
MDM2 would be expected to restore the apoptotic pathway in cancer cells that over-
express this protein (7).  This assumes that the cells still have normal expression of p53, 
which is typically the case (7).  There are certain types of cancers that are more likely to 
have higher levels of MDM2 over-expression, including soft tissue tumors, 
osteosarcomas, and gliomas (8). 
3.1.3 Inhibiting the MDM2/p53 Interaction with Small Molecules 
 
MDM2 is an attractive target for several reasons (9).  One of them is that the p53 
regulatory function of MDM2 has been well characterized at the biological level (9).  
Another reason is that the crystal structure of the MDM2/p53 binding complex has been 
known for the past ten years (9).  (The crystal structure of the MDM2/p53 complex is 
shown in panel A of Figure 3.6 below.)  And finally, experiments with site-directed 
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mutagenesis and peptide inhibitors have established a clearly-defined pharmacophore, 
such that the binding requirements of any anti-MDM2 drug are well understood (9).  
Several compounds have been reported that inhibit the p53-MDM2 interaction; in 
general, they mimic p53 as opposed to MDM2 (6).  This is because MDM2 (but not p53) 
has a well-defined binding site, and p53 (but not MDM2) has an interface comprised of a 
single, short stretch of amino acids arranged in an alpha helix secondary structure (6,7).  
The MDM2/p53 interaction has also been studied using molecular modeling in order to 
analyze the movements of both proteins when they are bound together versus unbound 
(10).  It was found that the conformation of MDM2 changes very little upon association 
with the p53 helix, suggesting that a good inhibitor of MDM2 can be developed (10).   
The first reported p53 inhibitors were phage-display peptide libraries that showed 
greater affinity for MDM2 than even p53 itself did (6).  The use of unnatural amino acids 
and conformational restrictions improved peptide potency even more, and also provided 
the proof of concept that inhibitors of MDM2 could block its interaction with p53 (6).  
Unfortunately, peptides do not make good drugs for many reasons, including their lack of 
oral bioavailability and their susceptibility to proteases (11).  Thus, several groups are 
working to make small-molecule inhibitors that can block MDM2/p53 interactions that 
would hopefully show improved drug-like properties in comparison to peptides.  
Until quite recently, it was believed that using small molecules to inhibit protein-
protein interactions would be difficult at best and impossible at worst (12).  However, 
there have now been several examples of small-molecule protein-protein inhibitors 
published.  These compounds can either act directly such that they inhibit the proteins 
from interacting, or indirectly at an allosteric site (12).  Although many protein-protein 
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interactions are difficult to disrupt using small-molecule inhibitors due to the lack of a 
well-defined binding pocket, the p53/MDM2 interaction is particularly attractive in this 
regard because the interface between the two molecules is relatively small, and it is 
known that p53 does bury itself into a pocket on MDM2 (7).   
 
 
 
 
 
Figure 3.4: Small Molecule Inhibitors of MDM2 (13).  Panel A is an example of a 
chalcone, and Panel B is a boronic chalcone.  Chlorofusin is shown in Panel C.  Panel D 
shows nutlin 2, the best currently known small-molecule inhibitor of MDM2. 
 
 
The first small-molecule inhibitors of MDM2 to be identified were chalcones, 
which are pictured in panel A of Figure 3.4 (13).  These compounds are weak MDM2 
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inhibitors with IC50 values in the high micromolar range (13).  Chalcones were known to 
have anti-tumor properties, and NMR studies showed that they bind to a portion of the 
p53-binding site on MDM2 (14).  In addition, biochemical experiments established that 
chalcones can disrupt MDM2/p53 interactions (14).  Boron-containing chalcone 
derivatives have also been described (13); an example is shown in panel B of Figure 3.4. 
Another MDM2 inhibitor is chlorofusin, a cyclic peptide derivative that was 
isolated and characterized from a microorganism associated with a Fusarium genus 
fungus (13,15).  The structure of chlorofusin is shown in Panel C of Figure 3.4.  It is 
comprised of a cyclic peptide with a non-peptide chromophore attached to it (15).  An 
examination of this structure shows that it is too large, complex, and peptide-like to be a 
good drug candidate.  The cyclic peptide portion of chlorofusin was synthesized and 
tested alone; it was found not to inhibit the p53-MDM2 interaction (16).  This suggests 
that the chromophore portion of the molecule may be needed for the compound’s activity, 
which is also in the micromolar range (13). 
Recently, the nutlins, a class of potent, orally bioavailable small-molecule 
inhibitors of the MDM2/p53 interaction were reported (17).  The nutlins were found to 
bind MDM2 in the p53 pocket, activate p53 in tumor cells, and induce apoptosis (17).  
They are active at a submicromolar level (17).  The structure of nutlin-2 is shown in 
panel D of Figure 3.4.  Nutlin-2’s crystal structure with MDM2 showed that nutlin-2 
closely mimics the binding properties of p53 (17).  In particular, three binding residues of 
p53 (Phe, Trp, and Leu) were all mimicked by nutlin-2, in contrast to previous inhibitors 
like the chalcones that only replaced a portion of the p53 alpha helix (13). 
 82
Biological tests with another compound, nutlin-3, showed that nutlin-3 selectively 
induces the p53 pathway, promoting cell cycle arrest and apoptosis in vivo as well as in 
vitro (18).  Cancer cells with over-expressed or even normal levels of MDM2 both 
showed sensitivity to nutlin-3, but only if p53 expression was normal (18).  Fortunately, 
it appears that most tumors that over-express MDM2 do not also have mutations of p53 
as well (18).  It seems reasonable that tumor cells that over-express MDM2 would most 
likely have intact p53 signaling, because further attenuation of p53 would not be 
necessary for them to avoid undergoing apoptosis (18). 
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Figure 3.5: Structure of syc-7, a Non-Peptide Inhibitor of HDM2 (19).  This 
compound and some of its derivatives were able to inhibit HDM2/p53 interactions and 
induce apoptosis in some tumor cell lines. 
 
 
Finally, there have also been a series of small-molecule inhibitors of the 
HDM2/p53 association reported (19).  These compounds, called syc compounds, were 
conceived using computer-aided design, and then synthesized (19).  One compound in 
particular, syc-7, showed an ability to inhibit HDM2-p53 interactions, and also could be 
seen to activate the p53 pathway and induce apoptosis in four different tumor cell lines 
(19).  However, the concentrations of syc-7 needed to induce apoptosis were 
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prohibitively high for a drug, in the low millimolar range (19).  The structure of syc-7 is 
shown in Figure 3.5. 
3.1.4 Inhibiting MDM2/p53 with Peptides and Peptidomimetics 
 
As mentioned previously, the first inhibitors of the MDM2/p53 interaction were 
peptides and modified peptides obtained by screening phage libraries, reported in 1996 
(6,20).  These researchers originally used peptides to establish the p53 pharmacophore, 
and they discovered that the hexapeptide Thr-Phe-Ser-Asp-Leu-Trp was the consensus 
sequence (20).  However, this peptide had fairly low binding affinity that was in the 
micromolar range (20).  Somewhat better results were obtained by screening a phage 
display peptide library, which improved the binding affinity by 28-fold (20).  Starting 
with an octapeptide lead, the binding affinity of this peptide for HDM2 was improved 
even more to the low nanomolar range by replacing non-pharmacophore amino acids 
with α,α-disubstituted amino acids (20).  It is known that the use of disubstituted amino 
acids can stabilize the α-helix secondary structure of a short peptide (20). 
More recently, Andy Hamilton’s group at Yale has made a variety of α-helix-like 
peptidomimetics based on a terphenyl scaffold (21,22).  The substituents on the benzene 
rings in these structures are too close together to allow the benzene rings to be coplanar, 
which gives the molecule a twisted or helical shape.  Placing substituents at the ortho 
positions on each benzene ring orients these substituents so that they mimic the 
orientation of the amino acid side chains on an alpha helix (21,22).  The relationship 
between Hamilton’s helices and the p53 α-helix can be seen in Figure 3.6.  Panel A 
shows the crystal structure of p53 interacting with MDM2.  The orientation of the side 
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chains at the i, i+4, and i+7 positions can be seen in p53 versus a terphenyl helix in Panel 
B.  (These are the essential Phe, Trp, and Leu residues identified previously.)   
 
 
 
Figure 3.6: Design, Model, and Structures of Hamilton’s Terphenyl Helices (21, 22).  
Panel A shows the x-ray crystal structure of p53 (backbone) complexed with MDM2 
(space-filling).  Panel B shows how the physical topography of an α-helix is mimicked 
by the Hamilton helices.  Several examples of Hamilton helices that were screened 
against MDM2 are shown in Panel C. 
 
 
 
Hamilton’s group discovered that the best inhibition occurred with the use of an 
isobutyl or benzyl group on the first phenyl ring, mimicking Phe (22).  In addition, it was 
helpful to have an extra methyl side chain on the second phenyl ring, since this made the 
compound more rigid and better able to induce activation of p53 (22).  Fortuitously, it 
was found that several of the terphenyl compounds were membrane-permeable, and they 
could induce p53 activation and accumulation in tumor cells (22).  Several examples of 
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p53-like terphenyl helices are shown in Panel C.  Other terphenyl helices have been 
developed as mimics of the Bak BH3 domain; this work will be discussed further in 
Chapter Four. 
3.2 Results and Discussion 
 
Although Hamilton’s helices seem like a promising idea for p53 mimics, they do 
have the disadvantage of being nonpolar and therefore not very water-soluble.  They are 
also difficult to synthesize.  Accordingly, we have designed a new set of p53 helices 
based on hydrazino subunits that can be assembled into a set of piperazine dione rings, as 
shown in the top panel of Figures 3.7.  As with Hamilton’s terphenyl helices, the 
McLaughlin compounds are also predicted to form a twisted shape based on molecular 
models.  The model is shown in the bottom panel of Figure 3.7.  
 
 
 
 
Figure 3.7: Structure and Model of the McLaughlin Piperazine Helix.  Not only does 
this helix twist like the Hamilton Helix does, it has the additional advantage of being 
more polar and water-soluble.  The building blocks of the helix can be synthesized from 
ordinary natural or unnatural amino acids, allowing for a great diversity of side chains. 
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The chemistry to make piperazine diones is well known, and there are several 
examples in the medicinal chemistry literature (23).  These compounds can be made from 
ethylene diamine tetraacetic acid tetraethyl ester scaffolds (23).  Members of several 
classes of drugs contain piperazine diones, including topoisomerase inhibitors, tricyclic 
anti-depressants, and antihistamines (23).  In addition, these compounds can be made 
using solid-phase synthesis, as well as in solution (24).  As far as we are aware, there are 
currently no examples in the literature of hydrazino piperazine diones from amino acids. 
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Figure 3.8: Synthesis of McLaughlin Piperazine Dione α-Helix Mimics.  The 
hydrazino units will be incorporated into piperazine dione peptidomimetics via solid-
phase synthesis.  X represents an activated carboxylic acid; R is an amino acid side chain. 
 
 
The McLaughlin helices have the advantage of being amenable to solid-phase 
peptide synthesis, thus facilitating their construction.  They also have the advantage that 
multiple natural and unnatural amino acid side chains can be inserted into the 
peptidomimetic.  Figure 3.8 shows how the hydrazino subunits can be combined into the 
piperazine dione compound.  Compounds 17a–c and other alkylated hydrazino amino 
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acids can be incorporated into the piperazine dione alpha helix mimics described above.  
This is currently being done in our lab via solid-phase synthesis through a series of 
deprotection, activation, and coupling steps. The synthesis of hydrazines 17a-c is 
discussed below. 
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Scheme 3.1: Synthesis of Alkylated Hydrazino Amino Diacids.  N-amination of the 
three alkylated amino acids with oxaziridine 10 (25,26) was the key step in this synthesis.  
Hydrolysis of hydrazine 16a gave product 17a.  The synthesis of compounds 16b-c and 
17b-c was not completed. 
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Scheme 3.2: Synthesis of Tryptophan Methyl Esters 14b and 14c.  Both compounds 
were prepared via a series of protection and deprotection steps from commercially 
available Cbz-tryptophan.  Each of these steps proceeds with approximately quantitative 
yields. 
 
 
 Hydrazino amino acid derivative 17a was synthesized to be used as a subunit in 
the construction of the McLaughlin helices.  It was synthesized using the procedure 
depicted in Scheme 3.1.  The methyl ester of the amino acid 14a was first reacted with 
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ethyl bromoacetate in the presence of diisopropylethylamine to form secondary amine 
15a.  This compound was then reacted with oxaziridine 10 (25, 26) to give the Boc-
protected hydrazine 16a.  Oxaziridine 10 here is the same compound that was used 
previously to synthesize compound 5b, as described in Chapter Two.  The final step in 
the synthesis was to hydrolyze both esters using lithium hydroxide to give 17a.  The 
synthesis of two other hydrazino amino acid derivatives (17b-c) was partially completed. 
The isoleucine methyl ester 14a was commercially available as the hydrochloride 
salt, but the two tryptophan methyl esters 14b and 14c had to be synthesized from 
commercially available compound 18 as shown in Scheme 3.2.  Compound 18 is the Cbz-
protected amino acid tryptophan.  The first step was to make the methyl ester 19a of 18 
using potassium carbonate and methyl iodide.  Compound 19a was then split into two 
portions.  One portion was hydrogenated to directly form compound 14b, which was then 
used to form the hydrazine diacid 17b as shown in Scheme 3.1.  The other portion was N-
alkylated on the indole nitrogen to give 19b, and compound 19b was then also 
hydrogenated to form the alkylated indole tryptophan ester 14c.  Finally, compound 14c 
was converted into hydrazine diacid 17c, also shown in Scheme 3.1.  
Initially, our synthetic procedure called for using sodium hydroxide to hydrolyze 
the esters rather than lithium hydroxide.   This procedure worked fine for some of the 
first amino acids tried, which included phenylalanine and leucine.  However, the hindered 
amino acids valine and isoleucine did not hydrolyze to the diacid with NaOH.  Instead, 
treatment of isoleucine hydrazine diester 16a with NaOH consistently yielded monoacid 
20 instead of the desired diacid 17a.  We tried refluxing 16a for 48 hours using NaOH, 
but we still could not obtain the diacid.  However, we finally were able to obtain 17a 
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when we used lithium hydroxide.  Subsequent attempts at hydrolysis of 16a with NaOH 
were finally successful, but doing this required harsh conditions that might lead to the 
racemization of the alpha carbon.  However, we did not observe any such racemization. 
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Scheme 3.3: Results of the Hydrolysis of 16a with NaOH versus LiOH.  Unlike the 
less hindered amino acids, use of NaOH to hydrolyze the Ile diester led to the monoacid 
product 20 rather than the desired diacid 17a.  Compound 17a was ultimately obtained by 
hydrolysis of 16a with LiOH. 
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Figure 3.9: MDM2 Small-Molecule Inhibitor Lead Compound NSC-131734.  Our 
analogs 23 attempted to mimic the quinoline and anthracene systems of this compound, 
and all three compounds could be synthesized easily in a single step. 
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Scheme 3.4: Synthesis of MDM2 Inhibitors 23a-c.  All three compounds were 
synthesized in a single step from 1-(chloromethyl)naphthalene and the appropriate indole 
or carbazole derivative. 
 
 
We have also been working on the design and synthesis of a small library of 
small-molecule inhibitors of MDM2.  One compound that showed modest MDM2 
inhibitory activity was NCI compound NSC-131734, shown in Figure 3.9.  Three mimics 
23 of NSC-131734 were easily synthesized using similar chemistry as previously 
described for the tryptophan alkylation.  This procedure is shown in Scheme 3.4.  2,3-
dimethylindole (21a), carbazole (21b), and 1,2,3,4-tetrahydracarbazole (21c) were each 
treated with sodium hydride and then 1-(chloromethyl)-naphthalene (22) to give N-
alkylated products 23.   
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All three of these compounds were tested as inhibitors of MDM2 and were found 
to be inactive.  This may be due to their hydrophobicity, as all three compounds are 
insoluble in water and are significantly less polar than the model NCI compound.  It may 
also be due to the molecules being too small to adequately cover the entire p53 binding 
pocket on MDM2.  
In conclusion, we successfully carried out the synthesis of isoleucine hydrazino 
amino acid derivative 17a.  We also made progress toward the synthesis of two 
tryptophan hydrazino acid derivatives 17b-c.  Finally, we synthesized three potential 
small-molecule inhibitors (23a-c) of MDM2 that were modeled after a screened NCI 
compound.  Further work on this project will entail completion of the syntheses of 17b-c, 
assembly of the hydrazino amino acid derivatives into piperazine diones, and further 
biological testing of both the piperazine diones and the small-molecule inhibitors 23. 
3.3 Experimental Data 
 
Experimental Procedure for N-Alkylation.  The free amine 14 (5.50 mmol) was 
dissolved in acetonitrile (10 mL).  Diisopropylethylamine (11.01 mmol) and ethyl 
bromoacetate (16.51 mmol) were added via syringe.  The reaction was stirred overnight 
in an argon atmosphere at room temperature.  The resulting product was washed with 5% 
citric acid, the organic layer was separated, and the aqueous layer was extracted with 
ethyl acetate (3 x 20 mL).  The combined organic layers were washed with brine (1 x 20 
mL), dried with magnesium sulfate and evaporated under reduced pressure, yielding a 
yellow oil. The crude product was purified by column chromatography (4:1 
hexane/EtOAc) to give pure 15, a colorless oil. 
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15a  
Methyl N-(2-Ethoxy-2-Oxoethyl)-(S)-Isoleucinate (15a).  Rf = 0.62 (3:1 hexanes 
/EtOAc); 1H NMR (400 MHz, CDCl3) δ 0.82-0.86 (m, 6 H), 1.12-1.22 (m, 4 H), 1.45-
1.51 (m, 1 H), 1.63-1.69 (m, 1 H), 1.96 (s, 1 H), 3.08 (d, J = 6.0 Hz, 1 H), 3.24 (d, J = 
17.2 Hz, 1 H), 3.34 (d, J = 17.2 Hz, 1 H), 3.65 (s, 3 H), 4.11 (q, J = 7.2 Hz, 2 H); 13C 
NMR (100 MHz, CDCl3) δ 11.62, 14.33, 15.72 25.63, 38.48, 49.94, 51.65, 60.90, 65.76, 
171.96, 174.83 ppm; MS (GC/MS) m/z 232, 199, 172, 158, 146, 130, 114, 100, 86, 69, 
56. 
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Methyl N-(2-Ethoxy-2-Oxoethyl)-(S)-Tryptophanate (15b).  Rf = 0.73 (100% 
EtOAc), Rf = 0.04 (3:1 hexanes /EtOAc); 1H NMR (400 MHz, CDCl3) δ 1.19 (t, J = 6.8 
Hz, 3H), 2.37 (broad, 1H), 3.14-3.19 (m, 1H), 3.26 (dd, J = 6.0 Hz, 14.4 Hz, 1H), 3.32-
3.36 (m, 1H), 3.45-3.49 (m, 1H), 3.66 (s, 3H), 3.72 (t, J = 6.0 Hz, 1H), 4.10 (q, J = 6.8 
Hz, 2H), 7.10-7.13 (m, 2H), 7.16-7.20 (m, 1H), 7.34 (d, J = 8.0 Hz, 1H), 7.60 (d, J = 7.6 
Hz, 1H), 8.27 (broad, 1H); 13C NMR (100 MHz, CDCl3) δ 14.32, 29.33, 49.45, 52.17, 
61.11, 61.38, 110.94, 111.48, 118.87, 119.68, 122.31, 123.33, 127.60, 136.48, 171.84, 
174.59; HR ESI-MS (0.1% AcOH in MeOH) 327.13188 (M + Na)+  
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Methyl N’-Methyl-N-(2-Ethoxy-2-Oxoethyl)-(S)-Tryptophanate (15c).  Rf = 0.81 
(100% EtOAc), Rf = 0.12 (3:1 hexanes /EtOAc); 1H NMR (400 MHz, CDCl3) δ 1.22 (t, J 
= 7.2 Hz, 3H), 2.17 (broad, 1H), 3.14 (dd, J = 7.2 Hz, 14.8 Hz, 1H), 3.24 (dd, J = 5.6 Hz, 
14.4 Hz, 1H), 3.31-3.36 (m, 1H), 3.44-3.3.50 (m, 1H), 3.66 (s, 3H), 3.70 (t, J = 5.6 Hz, 
1H), 3.75 (s, 3H), 4.11 (q, J = 7.6 Hz, 2H), 6.98 (s, 1H), 7.09-7.13 (m, 1H), 7.20-7.24 (m, 
1H), 7.26-7.30 (m, 2H), 7.59 (d, J = 8.0 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 14.30, 
28.70, 32.96, 49.03, 52.40, 61.24, 61.44, 108.66, 109.57, 118.91, 119.30, 122.00, 127.98, 
128.27, 137.27, 170.92, 172.76; HR ESI-MS (0.1% AcOH in MeOH) 341.14739 (M + 
Na)+ 
 
Experimental Procedure for Hydrazine Formation (16a-c).  Compound 15 (5.75 
mmol) was dissolved in methanol (12 mL) in a round bottom flask and cooled to –78 °C 
under an argon atmosphere.  Oxaziridine 10 (6.55 mmol, Ref. 25,26) was dissolved in 
methanol (10 mL) and added to the reaction mixture slowly via syringe, and the reaction 
was allowed to warm to room temperature and stirred overnight. The reaction was then 
washed with water, the organic layer was separated, and the aqueous layer was extracted 
with ethyl acetate (3 x 20 mL).  The combined organic layers were washed with brine (1 
x 25 mL), dried with magnesium sulfate and evaporated under reduced pressure.  The 
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crude product was purified by column chromatography (9:1 hexane/EtOAc) to give pure 
16, a colorless oil. 
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16a  
Methyl N”-tert-Butoxycarbonyl-N-(2-Ethoxy-2-Oxoethyl)-(S)-Isoleucinate (16a). Rf  
= 0.53 (3:1 hexane/EtOAc); 1H NMR (400 MHz, CDCl3) δ 0.83-0.94 (m, 6 H), 1.16-1.22 
(m, 1H), 1.23 (t, 3 H), 1.44 (s, 9 H), 1.74-1.78 (m, 1 H), 1.95-2.01 (m, 1H), 3.16-3.21 (m, 
1H), 3.57-3.61 (m, 1 H), 3.69-3.76 (m, 4 H), 4.15 (q, J = 7.2, 2H), 7.21 (broad, 1H); 13C 
NMR (100 MHz, CDCl3) δ 11.03, 11.67, 14.33, 14.37, 15.47, 15.74, 25.71, 28.18, 28.41, 
28.47, 34.91, 38.47, 49.92, 51.47, 51.75, 56. 55, 60.93, 61.03, 65.78, 71.99, 80.15, 
170.52, 171.91, 172.89, 174.76 ppm; MS (GC/MS) m/z 346, 287, 273, 246, 231, 217, 
189, 173, 157, 145, 129, 113, 101, 87, 69, 57; HR ESI-MS (0.1% AcOH in MeOH) 
369.19977 (M + Na)+  
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Procedure for N”-tert-Butoxycarbonyl-N-(2-Ethoxy-2-Oxoethyl)-(S)-Isoleucinate 
Synthesis (20). Compound 16a (0.75 mmol) was dissolved in methanol (3 mL), and 1.87 
mL of a 1.0 solution of sodium hydroxide was added to it by syringe.  The reaction was 
stirred for four hours at RT.  The resulting product was washed with potassium bisulfate.  
The organic layer was separated and the aqueous layer was extracted with ethyl acetate (3 
x 10 mL).  The combined organic layers were washed with brine (1 x 15 mL), dried with 
magnesium sulfate and dried under reduced pressure, yielding 20 (0.21 g, 79%), a 
colorless oil; Rf = 0.69 (9:1 DCM/MeOH); 1H NMR (400 MHz, CDCl3) δ 0.80-0.86 (m, 6 
H), 1.14-1.19 (m, 1 H), 1.40 (s, 9 H), 1.73-1.76 (m, 1 H), 1.77-1.89 (m, 1H), 3.16 (d, J = 
9.6 Hz, 1 H), 3.45-3.54 (m, 2 H), 3.71 (s, 3 H), 7.21 (broad, 1H); 13C NMR (100 MHz, 
CDCl3) δ 11.14, 15.70, 26.26, 28.36, 28.41, 35.50, 52.12, 72.74, 82.78, 158.00, 171.17 
ppm; ESI-MS (0.1% AcOH in MeOH) 317.1 (M - H)- 
 
Procedure for Diacid Synthesis. Compound 16a (0.45 g, 1.3 mmol) was dissolved in 
methanol (13 mL).  0.5 M lithium hydroxide (9.29 mL) was added, the flask was heated 
to 50 °C and stirred for 24 hours. The resulting product was washed with potassium 
bisulfate.  The organic layer was separated and the aqueous layer was extracted with 
ethyl acetate (3 x 10 mL).  The combined organic layers were washed with brine (1 x 15 
mL), dried with magnesium sulfate and dried under reduced pressure.  The crude product 
was recrystallized (DCM/hexane) yielding 17a (0.17g, 45%), a white solid. 
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N”-tert-Butoxycarbonyl-N-Carboxymethyl-(S)-Isoleucinate (17a). MP = 98-100 °C; 
Rf = 0.13 (9:1 DCM/MeOH); 1H NMR (400 MHz, CD3OD) δ 0.89-0.95 (m, 6 H), 1.17-
1.30 (m, 1 H), 1.46 (s, 9 H), 1.71 -1.87 (m, 2 H), 3.34-3.36 (m, 1 H), 3.64-3.69 (m, 2 H); 
13C NMR (100 MHz, CD3OD) δ 9.87, 10.41, 10.60, 14.55, 14.86, 15.38, 25.12, 25.61, 
26.03, 27.40, 34.38, 35.11, 35.45, 53.63, 57.82, 70.56, 71.82, 72.19, 80.83, 157.12, 
172.26, 174.07, 174.18, 174.74 ppm; ESI-MS (0.1% AcOH in MeOH) 303.1 (M - H)-  
 
19a
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Experimental Procedure for Methyl Esterification of N-Carboxybenzyl-(S)-
Tryptophanate to Methyl N-Carboxybenzyl-(S)-Tryptophanate (19a).  The 
commercially available Cbz- protected Trp 18 (1.48 mmol) was dissolved in dry DMF 
(20 mL) and cooled to 0 °C.  Anhydrous potassium carbonate (1.63 mmol) was added, 
and the reaction was flushed with argon and stirred at 0 °C for 10 minutes.  Methyl iodide 
 98
(2.96 mmol) was then added drop-wise via syringe, and the reaction was allowed to warm 
up to room temperature.  After stirring for 4.5 hours, the reaction was diluted with ethyl 
acetate (50 mL) and washed twice with saturated sodium bicarbonate solution.  The 
organic layer was then washed once with saturated NaCl solution, dried over MgSO4, and 
evaporated under reduced pressure.  The pure product 19a was isolated by filtering 
through a small pad of silica using 3:1 hexanes:ethyl acetate in 100% yield. Rf  = 0.59 
(1:1 hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) δ 3.31 (d, J = 5.6 Hz, 2H), 3.68 (s, 
3H), 4.71-4.75 (m, 1H), 5.07-5.15 (m, 2H), 5.42 (d, J = 8 Hz, 1H), 6.92 (s, 1H), 7.10 (t, J 
= 7.2 Hz, 1H), 7.19 (t, J = 7.6 Hz, 1H), 7.32-7.35 (m, 6H), 7.53 (d, J = 8.0 Hz, 1H), 8.42 
(broad, 1H); 13C NMR (100 MHz, CD3OD) δ 28.18, 52.61, 54.81, 67.19, 109.87, 111.59, 
118.78, 119.84, 122.39, 123.24, 127.76, 128.36, 128.41, 128.77, 136.44, 136.55, 156.12, 
172.74; ESI-MS (0.1% AcOH in MeOH) 353.1 (M + H)+ 
 
 
19b
N
OCbz
H O
N
 
 
Experimental Procedure to Form Methyl N’-Methyl-N-Carboxybenzyl-(S)-
Tryptophanate (19b).  The Trp methyl ester 19a (1.48 mmol) was dissolved in 25 mL 
anhydrous DMF and the reaction mixture was cooled to 0 °C.  Unwashed 60% sodium 
hydride was added slowly, and the reaction was stirred for fifteen minutes until all 
effervescence had ceased.  Then methyl iodide (1.63 mmol) was added, and the reaction 
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was allowed to warm to room temperature and stirred for three hours.  It was quenched 
with water, forming an oily white precipitate that could not be filtered.  The reaction 
mixture was acidified with 10% KHSO4 to pH = 3, and the aqueous layer was extracted 
three times with DCM.  The combined organic layer was then extracted twice with dI 
water and once with brine, dried over MgSO4, and evaporated under reduced pressure to 
give the pale yellow oil 19b in 77.8% yield.  Rf  = 0.67 (1:1 hexanes/EtOAc); 1H NMR 
(400 MHz, CDCl3) δ 3.33 (d, J = 5.6 Hz, 2H), 3.71 (s, 3H), 3.72 (s, 3H), 4.73-4.75 (m, 
1H), 5.10-5.18 (m, 2H), 5.40 (d, J = 8.0 Hz, 1H), 6.84 (s, 1H), 7.10-7.14 (m, 1H), 7.22-
7.37 (m, 7H), 7.54 (d, J = 8.0 Hz, 1H); 13C NMR (100 MHz, CD3OD) δ 28.04, 32.94, 
52.59, 54.81, 67.15, 108.45, 109.59, 118.98, 119.44, 122.05, 127.79, 128.20, 128.30, 
128.41, 128.78, 136.64, 137.19, 156.07, 172.69; ESI-MS (0.1% AcOH in MeOH) 367.1 
(M + H)+ 
 
 
Experimental Procedure to Remove the Cbz Protecting Group (14b-c).  The 
methylated tryptophan derivatives (0.426 mmol) were dissolved in a few mL of 
methanol/THF, to which was added 0.1 g 10% Pd/C and a couple of drops of glacial 
acetic acid.  This mixture was then placed in a hydrogen atmosphere at approximately 50 
psi and shaken for one hour, after which the Pd/C was removed by filtering the dissolved 
product through a Celite bed.  The product was obtained as a white solid in 100% yield.   
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Methyl (S)-Tryptophanate (14b).  MP = 101-103 °C;  Rf  = 0.08 (100 % EtOAc); 1H 
NMR (400 MHz, CD3OD) δ 3.59 (s, 3H), 4.00-4.03 (m, 1H), 6.89-6.91 (m, 1H), 6.95-
6.97 (m, 1H), 7.01 (s, 1H), 7.22 (d, J = 8.4 Hz, 1H), 7.37 (d, J = 8.0 Hz); 13C NMR (100 
MHz, CD3OD) δ 27.93, 52.60, 54.26, 107.63, 111.90, 118.22, 119.49, 122.13, 124.64, 
127.63, 137.55, 171.75; HR ESI-MS 219.11305 (0.1% AcOH in MeOH) (M + H)+  
 
14c
H
N
O
OH
N
 
Methyl N’-Methyl -(S)-Tryptophanate (14c).  MP = 105-106 °C;  Rf = 0.15 (100% 
EtOAc);  1H NMR (400 MHz, CDCl3) δ 3.07-3.13 (m, 1H), 3.29 (dd, J = 4.4 Hz, 14.4Hz, 
1H), 3.85-3.88 (m, 1H), 3.73 (s, 3H), 3.76 (s, 3H), 4.96 (broad, 2H), 6.94 (s, 1H), 7.11 (t, 
J = 8.0 Hz, 1H), 7.21-7.26 (m, 1H), 7.30 (d, J = 8.4 Hz, 1H), 7.58 (d, J = 7.6 Hz, 1H); 13C 
NMR (100 MHz, CDCl3) δ 30.27, 32.93, 52.35, 54.75, 109.27, 109.55, 119.03, 119.32, 
122.02, 128.05, 128.14, 137.30, 175.48; HR ESI-MS (0.1% AcOH in MeOH) 233.12831 
(M + H)+ 
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Procedure to Synthesize MDM2 Inhibitors.  60% sodium hydride (0.897 mmol) was 
washed two times with dry DMF to remove the oil, and then suspended in approximately 
ten mL dry DMF.  The reaction was cooled to 0° C, and then the indole or carbazole 
derivative (0.598 mmol) was added slowly.  The reaction mixture was then stirred for 
fifteen minutes at 0° C, after which 1-chloromethylnaphthalene (0.658 mmol) was added 
dropwise.  The reaction was allowed to warm up to room temperature and stirred at room 
temperature for five hours.  Ethyl acetate was then used to dilute the reaction, and it was 
washed three times with dI water and once with brine and dried over magnesium sulfate.  
Evaporation under reduced pressure yielded the crude product, which was recrystallized 
in ethyl acetate mixed with a few drops of hexanes to give the pure product in 66-91% 
yield. 
 
N
23a  
1-(1’-Methylnaphthyl)-2,3-Dimethylindole (23a).  MP = 150-152 °C; Rf  = 0.77 (3:1 
hexane/EtOAc); 1H NMR (400 MHz, CDCl3) δ 2.29 (s, 3H), 2.38 (s, 3H), 5.76 (s, 2H), 
6.37 (d, J = 6.8 Hz, 1H), 7.11-7.17 (m, 3H), 7.21-7.26 (m, 2H), 7.59-7.63 (m, 3H), 7.74 
(d, J = 8.4 Hz, 1H), 7.94 (d, J = 8.0 Hz, 1H), 8.14 (d, J = 8.4 Hz, 1H); 13C NMR (100 
MHz, CDCl3) δ 9.24, 10.21, 44.41, 107.40, 109.10, 118.32, 119.20, 121.10, 122.42, 
122.91, 126.06, 126.11, 126.62, 127.77, 129.02, 129.27, 130.53, 132.94, 133.39, 133.79, 
136.76; HR ESI-MS (0.1% AcOH in CH3CN) 286.1590 (M + H)+. 
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N
23b  
9-(1’-Methylnaphthyl)-Carbazole (23b).  MP = 146-148 °C; Rf = 0.73 (3:1 
hexane/EtOAc); 1H NMR (400 MHz, CDCl3) δ 5.94 (s, 2H), 6.68 (d, J = 7.2 Hz, 1H), 
7.20 (t, J = 7.6 Hz, 1 H), 7.30-7.32 (m, 2H), 7.34-7.38 (m, 2H), 7.43-7.48 (m, 2H), 7.64-
7.71 (m, 2H), 7.79 (d, J = 8.4 Hz, 1H), 7.99 (d, J = 8.8 Hz, 1H), 8.17 (d, J = 8.4 Hz, 1H), 
8.28 (d, J = 7.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 44.57, 109.31, 119.68, 120.78, 
122.61, 123.29, 123.44, 125.98, 126.25, 126.28, 126.80, 128.11, 129.41, 130.94, 131.94, 
134.04, 141.18; HR ESI-MS (0.1% AcOH in CH3CN) 308.1429 (M + H)+. 
 
N
23c  
9-(1’-Methylnaphthyl)-1,2,3,4-Tetrahydrocarbazole.  MP = 162-164 °C; Rf  = 0.76 
(3:1 hexane/EtOAc); 1H NMR (400 MHz, CDCl3) δ 1.92-1.93 (m, 4H), 2.62 (s, 2H), 2.86 
(s, 2H), 5.73 (s, 2H), 6.45 (d, J = 6.4 Hz, 1H), 7.10-7.17 (m, 3H), 7.23-7.27 (m, 1H), 
7.59-7.65 (m, 3H), 7.75 (d, J = 8.4 Hz, 1H), 7.94 (d, J = 7.6 Hz, 1H), 8.12 (d, J = 8.8 Hz, 
1H); 13C NMR (100 MHz, CDCl3) δ 21.45, 22.16, 23.46, 23.52, 44.08, 109.25, 110.33, 
118.10, 119.22, 121.10, 122.46, 123.02, 126.04, 126.09, 126.61, 127.76, 127.82, 129.26, 
130.58, 133.47, 133.79, 136.15, 136.99; HR ESI-MS (0.1% AcOH in CH3CN) 312.1743 
(M + H)+. 
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CHAPTER FOUR 
 
DESIGN AND SYNTHESIS OF A BAX PROTEIN α-HELIX MIMIC 
 
 
4.1 Introduction 
 
4.1.1 Pro-Apoptotic and Anti-Apoptotic Members of the Bcl-2 Family 
 
Apoptosis was discussed in the Introduction section of Chapter Three regarding 
the MDM2-p53 interaction.  As shown in Figure 3.2, there are two apoptotic pathways: 
the extrinsic (FAS) pathway, which involves death receptors; and the intrinsic 
(mitochondrial) pathway, which involves cytochrome c release from the mitochondria as 
a result of action by the Bcl-2 family of proteins (1).  This chapter will discuss some of 
the Bcl-2 family members, as well as ideas for manipulating them in order to promote 
apoptosis in cancer cells.  
The Bcl-2 family of proteins is comprised of three groups of pro-apoptotic and 
anti-apoptotic members (2,3), several of which are shown in Figure 4.1.  The top panel 
shows the Bcl-2 group, which includes Bcl-xL and Bcl-2; these proteins are anti-apoptotic 
(2).  They share a sequence homology to Bcl-2 in four regions that are designated Bcl-2 
homology one through four (BH1-BH4), as shown in Figure 4.1 (2).  The pro-apoptotic 
Bax group is shown in the middle panel; these proteins have three Bcl-2 homologous 
regions numbered from BH1-BH3 (2).  The Bik group members, shown at the bottom of 
Figure 4.1, are another set of pro-apoptotic proteins that only share homology in the BH3 
region (2). 
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Figure 4.1: The Bcl-2 Family of Proteins (2).  The Bcl-2 group proteins are anti-
apoptotic, while the Bax and Bik groups are both pro-apoptotic. 
 
 
It is the interplay of various Bcl-2 family members that determines the 
mitochondrial response, and ultimately the cell’s fate (3,4).  The Bcl-2 family proteins 
can form heterodimers between pro-apoptotic and anti-apoptotic members; this inhibits 
the biological activity of their partners (2-4).  Heterodimerization occurs via the BH3 
region of a pro-apoptotic protein being inserted into a hydrophobic cleft comprised of the 
BH1, BH2, and BH3 regions of an anti-apoptotic protein (2).  The BH1, BH2, and BH4 
regions are all necessary for anti-apoptotic activity, but BH3 alone is sufficient for pro-
apoptotic activity (2).  Some of the pro-apoptotic family members like Bax and Bak can 
also form homo-oligomers that allow for outer mitochondrial membrane permeabilization 
in response to a loss of the mitochondrial proton gradient (3).   
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Originally, it was thought that any of the pro-apoptotic proteins could pair up with 
any of the anti-apoptotic ones (4).  However, it is now known that several of the Bcl-2 
family members have specificities for certain partners and not for others (4).  It appears 
that many of the BH3-only pro-apoptotic family members interact with certain anti-
apoptotic partners, and that once these anti-apoptotic proteins are neutralized, the pro-
apoptotic Bax group of proteins are free to permeabilize the mitochondria and other 
organelles (4).  There are, however, some BH3-only pro-apoptotic proteins that can pair 
with any of the anti-apoptotic proteins; one consequence of this differential specificity is 
that the BH3-only proteins with more specificity are weaker cell killers in comparison to 
the broader-spectrum BH3-only proteins (4).  It has been suggested that the more specific 
binding properties of some proteins may be due to their greater rigidity, while the more 
general binding properties of other proteins occur because they are more flexible (4). 
Several members of the Bcl-2 family can form channels in the mitochondrial 
membrane, including Bax, Bcl-2, and Bcl-xL (5).  The pro-apoptotic Bax presumably 
forms channels to permit the escape of cytochrome c from the mitochondria, but it is not 
known what the purpose is of the channels formed by the anti-apoptotic Bcl-2 proteins 
(5).  Presumably, their channel-forming activity relates to promoting cell survival (5). 
It is not precisely known how pro-apoptotic family members like Bax are able to 
cause mitochondrial rupture and cytochrome c release, but some of the details have been 
worked out.  One thing that is known is that the ability of Bax to form channels in the 
mitochondria is pH-dependent (5).  A proposed mechanism for the Bax channel-forming 
process is shown in Figure 4.2 (6).  There are several steps that are necessary before 
apoptosis can occur.   
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Under normal, non-apoptotic conditions, a mitochondrion is characterized by a 
proton gradient across its inner membrane.  The cytochrome c molecules are located in 
the intermembrane space on the mitochondrial inner membrane (MIM).  Bax is soluble in 
the cytoplasm of the cell.  A protein called the permeability transition pore (PTP), which 
spans both the MIM and the mitochondrial outer membrane (MOM) in its active form, is 
inactive under normal conditions.  This scenario is depicted in Panel A of Figure 4.2 (6). 
 
 
 
Figure 4.2: Theorized Mechanism of Action of Bax (6).  Panel A shows the normal 
mitochondrial membrane, with Bax solubilized in the cytoplasm and a proton gradient 
across the mitochondrial membrane.  In Panel B, the proton gradient has been dissipated, 
which causes a conformational change in Bax and allows it to insert its 9th alpha helix 
into the mitochondrial membrane (Panel C).  The Bax helices form channels that allow 
the cytochromes to escape into the cytoplasm (Panel D), thereby killing the cell. 
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The first thing that must happen in order for Bax-induced apoptosis to occur is 
that the mitochondrial proton gradient must be lost.  There are two proteins that comprise 
the PTP, called the voltage-dependent anion channel (VDAC) and the adenine nucleotide 
transporter (ANT).  VDAC, which is in the MOM, and ANT, which is in the MIM, 
associate to form the PTP, which spans both membranes (2).  The PTP opens, allowing 
protons to move down their electrochemical gradient and enter the mitochondrial matrix.  
The proton gradient is thus dissipated (6), as shown in Panel B of Figure 4.2. 
The loss of the mitochondrial proton gradient causes a conformational change in 
Bax.  Individual Bax proteins begin to insert their C-terminal α-helices into the MOM 
(6).  This is shown in Panel C of Figure 4.2.  As the Bax proteins continue to insert into 
the mitochondrion, they begin to oligomerize and form channels in the MOM.  These 
channels allow the cytochrome c proteins in the intermembrane space to pass through the 
MOM into the cytoplasm, where they recruit the caspases that ultimately cause cellular 
death (6).  Panel D depicts the Bax oligomer channels allowing the cytochrome c 
molecules to escape from the mitochondrion into the cytoplasm. 
4.1.2 Mimicking the BH3 Domain of Pro-Apoptotic Proteins 
 
 To date, there have been several examples of small molecules, natural products, 
antisense nucleotides, peptides, and peptidomimetics that inhibit the Bcl-2 family protein 
interactions reported in the literature (7-23).  Generally, these compounds interfere with 
the interactions between the pro-apoptotic and anti-apoptotic family members.  For 
example, the Bcl-2 antisense nucleotide ODN 2009 was found to induce apoptosis in 
leukemia cells, and to work synergistically with the cytotoxic compound chlorambucil 
(7).  Several small molecules have been reported that inhibit the interactions between pro-
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apoptotic BH3 domains and Bcl-xL (8) and Bcl-2 (9-11).  These compounds were also 
found to promote apoptosis in tumor cells; their structures are shown in Figure 4.3. 
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Figure 4.3: Structures of Some Small-Molecule Bcl-2 Family Inhibitors (8, 9).  The 
first two compounds inhibit Bcl-xL, and the third compound inhibits Bcl-2. 
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Figure 4.4: Structures of Two Pro-Apoptotic Natural Products (12, 13).  These 
compounds are two natural products that were found to promote apoptosis. 
 
 
There are also natural products that have been reported to promote apoptosis (12-
13).  One is a methoxy derivative of antimycin A, shown on the right side of Figure 4.4.  
This compound competes with the Bak BH3 peptide to bind to Bcl-2 and Bcl-xL (12).  
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Another pro-apoptotic compound that was recently reported is alisol B acetate, shown on 
the left side of Figure 4.4.  This compound was found to induce Bax up-regulation and 
the insertion of Bax into the nuclear membrane (13).  Alisol B acetate does not affect the 
levels of the anti-apoptotic proteins Bcl-2 and Bcl-xL (13), suggesting that its mechanism 
of action (up-regulation of Bax) is different than that of most of the previous compounds 
discussed, which function by inhibiting the anti-apoptotic proteins. 
It is known that the interface between the anti-apoptotic proteins and the pro-
apoptotic BH3 helices is not flat; in fact, the BH3 helices bind in a groove on their anti-
apoptotic partners (14).  This fact makes the normally difficult process of finding a small-
molecule inhibitor of a protein-protein interaction seem more hopeful.  However, all of 
the small-molecule and natural product apoptosis promoters described thus far are active 
in the low micromolar concentration range, which is considerably higher in comparison 
to the natural BH3 helix ligands (14).  In addition, it is known that the BH3 domain is 
unstructured in solution, but it takes on a helical conformation when it binds to its anti-
apoptotic partner (14).  Thus, it is reasonable to propose that rigid, α-helix-mimicking 
compounds should have higher affinity and possibly higher specificity than the natural 
ligands do, since their binding would not result in as large of an entropic penalty due to 
the loss of conformational degrees of freedom (14).   
One group reported a protein grafting method where the active BH3 amino acid 
side chains were strategically placed on a rigid helical scaffold (15).  This design was 
then followed by a peptide selection process using phage display libraries where the 
peptides that were the most stable and had the best binding were selected (15).  The best 
proteins were found to have dissociation constants in the nanomolar range that were even 
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superior to the BH3 helix itself (15).  These authors also reported that the BH3-binding 
pockets on Bcl-2 versus Bcl-xL are different enough to make it possible to develop 
inhibitors specific to one protein over the other (14,15). 
More recently, a hydrocarbon stapling strategy was reported where BH3 peptides 
that had been chemically constrained into the helical binding shape were used to inhibit 
Bcl-2 (16).  These compounds were found to also be resistant to proteases and permeable 
to cell membranes, as well as having improved affinity for Bcl-2 in comparison with the 
native BH3 peptide (16).  As with the grafted peptides, these compounds were able to 
activate apoptosis in cancer cells (16). 
Finally, it is also possible to inhibit the anti-apoptotic proteins using 
peptidomimetics that are similar to the BH3 peptides, but that have entirely different 
scaffolds (17-23).  Several scaffolds have been reported, including oligoamide foldamers 
(17), terphenyl derivatives (18-21), and terephthalamide derivatives (21-22).  These 
compounds are shown in Figures 4.5, 4.6, and 4.7 respectively. 
 
 
Figure 4.5: Chemical and Stereo X-Ray Structure of an Oligoamide (17).  This 
compound is flat, but the isopropyl ether side chains twist out of the plane at a 45° angle. 
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 The oligoamide compounds were shown to have a flat backbone, but their side 
chains twist out of the plane at a 45° angle, as shown in Figure 4.5 (17).  These 
compounds were found to have a low micromolar affinity for Bcl-xL, which is about an 
order of magnitude worse than the binding affinity of the native BH3 peptide ligand (17).  
Attempts to lengthen the backbone to four units were unsuccessful due to the insolubility 
of the compound, and hydrolyzing the ester to improve solubility did not improve the 
affinity of the longer peptidomimetic (17).  
 
 
 
Figure 4.6: Terphenyl Derivatives with Binding Affinity for Bcl-xL (21).  Panel A 
shows a schematic of how the terphenyl mimics the side chain orientation on the BH3 
helix.  The crystal structure of the terphenyl is overlaid with an α-helix in Panel B. 
 
 The use of a terphenyl backbone was even more successful (18-21).  These so-
called “proteomimetics” have several advantages over the molecules previously 
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described, including their modular synthesis from subunits, their ability to project the side 
chains in the same orientation as the native BH3 peptide, and their twisted shape that 
mimics an α-helix (18).  The phenyl rings in the backbone are able to rotate around the 
single bonds between them, but the bulky side chains prevent them from being able to lie 
flat (19).  These compounds had binding constants for Bcl-xL in the high nanomolar 
range (20).  In the minimum energy conformation, the ortho substitution pattern on the 
terphenyl backbone mimics the i, i+4, and i+7 side chains on the BH3 helix; these are the 
residues that are important for BH3 to be able to interact with Bcl-xL (21).  The structure 
of these compounds is shown in Figure 4.6. 
 
 
Figure 4.7: Terephthalamide Derivatives with Binding Affinity for Bcl-xL (23).  
Panel A shows the general structure of the terephthalamide derivatives.  The overlap of a 
terephthalamide with an α-helix is shown in Panel B, while Panel C shows the overlap of 
a terphenyl compound with a terephthalamide. 
 
 
 The authors note that the terphenyl derivatives were too hydrophobic to be water-
soluble and that they were difficult to synthesize (22).  Thus, they developed a new 
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proteomimetic based on a terephthalamide scaffold, which is shown in Figure 4.7.  
Basically, the two terminal phenyl rings of the terphenyl were replaced with carboxamide 
groups, which also have a restricted geometry due to the planar amide bonds they contain 
(22).  This compound maintained the side chain geometry of the terphenyl compounds, 
while increasing the hydrophilicity of the backbone (22).  The terephthalamides were 
tested against Bcl-xL and found to be high nanomolar inhibitors, similar to their terphenyl 
predecessors (23). 
 All of the peptidomimetics described thus far function by affecting the pairings of 
pro-apoptotic BH3 proteins with anti-apoptotic Bcl-2 family proteins.  These compounds 
affect the apoptotic pathway upstream of the Bax family members, which form the 
membrane channels that release cytochrome c from the mitochondria.  A search of the 
literature did not turn up any compounds that directly affect Bax itself with the possible 
exception of alisol B.  The remainder of this chapter will discuss the effort to design and 
synthesize an α-helix mimic that could bind to Bax itself, thus forcing Bax to adopt its 
active, channel-forming conformation and ultimately inducing apoptosis. 
4.2 Results and Discussion 
 
The Bax protein is comprised of nine α-helices (24).  The first eight helices 
resemble the anti-apoptotic protein Bcl-xL, while the ninth C-terminal helix is involved 
with Bax dimerization and mitochondrial pore formation (24).  When Bax is in its 
inactive conformation, the ninth helix is tucked into a hydrophobic pocket formed by the 
rest of the protein (24).  Early in the apoptosis process, helix 9 inserts itself into 
mitochondrial membranes and forms the channels that permit cytochrome c to escape into 
the cytoplasm (24).  The structure of Bax is shown in Figure 4.8. 
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It is known that disruption of the inactive structure of Bax by detergents will 
cause oligomer formation (24).  Presumably, these oligomers would lead to membrane 
penetration, cytochrome release, and apoptosis.  We therefore propose a novel compound 
that is hypothesized to disrupt the inactive conformation of Bax, leaving the hydrophobic 
helix 9 free to insert into the mitochondrial membranes. 
 
 
 
Figure 4.8: Structure of the Pro-Apoptotic Bax Protein.  The apoptosis-inducing α-
helix 9 can be seen at the top of the picture, horizontal and nearest to the viewer. 
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We began by virtually screening a library of 1981 NCI compounds (~2500 3D 
models) in an effort to fit them into the hydrophobic binding site of helix 9 using the 
GLIDE automated docking program.  Since the binding site of the helix is relatively 
large, we obtained compounds that docked into the C-terminal, N-terminal, and middle 
portions of the Bax molecule.  A sample of the compounds that were found to dock to 
Bax is shown in Figure 4.9.  An examination of these molecules shows that they have 
several characteristics in common, including that they tend to be relatively symmetrical, 
contain aromatic rings, and unsurprisingly tend to be relatively hydrophobic.  
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Figure 4.9: Structures of Some NCI Compounds Virtually Screened to Fit into the 
Hydrophobic Pocket of Bax.  The hit compounds tend to be relatively symmetrical, 
nonpolar, and aromatic. 
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We then began a series of iterations to build up these small molecules into larger 
molecules that could occupy the entire helix 9 binding site.  This required several rounds 
of design and screening.  Although we initially built upon all four of the compounds 
shown in Figure 4.9, we discovered that the ligands with the best docking scores were 
derivatives of compound NSC109816.  We also found that the best compound 24 
contained an additional central carbonyl, and that molecular symmetry was apparently 
helpful.  Some of the intermediate compounds that evolved between the starting 
compound NSC109816 and the final compound 24 are shown in Figure 4.10.  
 
 
 
 
 
Figure 4.10: Some Iterations to Obtain Compound 24 from NSC 109816.  Each 
successive group of compounds was virtually screened, and the results were used to 
design the next set.   Eventually, this process resulted in compound 24, the synthesis of 
which is discussed below. 
 
 
 Based on the GLIDE docking simulations, compound 24 was predicted to have a 
similar shape and binding orientation in comparison to helix 9, and to fit into the same 
N N
O
H
HO
NSC109816
OH
OH
CH3
O
NHN
N
NH
NH
NH
O
O
ONH
N
NH
O
NN
H H
NNO O
N N
N N
24
 120
hydrophobic binding pocket.  Although the compound structure appears to be flat, the 
model predicts that 24 will exist in a twisted conformation, making its shape more 
analogous to an α-helix.  The structure of 24, its orientation according to the GLIDE 
model, and helix 9 are all shown in Figure 4.11. 
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Figure 4.11: Mimicking the Alpha Helix of Bax.  The bottom panel shows the alpha 
helix from the Bax protein.  Analogously, target compound 24 twists like an alpha helix, 
shown in the middle panel.  The chemical structure of 24 is shown in the top panel.    
 
 
 A superimposition of compound 24 with the Bax protein minus helix 9 is shown 
in Figure 4.12.  This diagram shows that 24 is large enough to occupy most of the 
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hydrophobic helix 9 binding pocket.  It also shows the twisted conformation of 
compound 24. 
 
 
 
 
 
Figure 4.12: Compound 24 Docked to Bax in Lieu of the Helix.  Computer 
simulations predict that 24 will bind Bax in the same orientation and place where helix 9 
normally folds. 
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 The remainder of this discussion presents our progress toward the synthesis of 
compound 24.  Scheme 4.1 shows the retrosynthesis of 24.  Since 24 is a symmetrical 
compound, only one half of the molecule must be synthesized, and the two identical 
pieces can then be joined together as a urea to make the entire compound.  Each half of 
24 was further broken down into an indole portion 25 and a benzoic acid portion 26.  
These two pieces are theoretically accessible from available starting materials 27 and 29. 
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Scheme 4.1: Retrosynthesis of Compound 24.  24 is a dimer requiring two pieces: 
indole derivate 25, and benzoic acid derivative 26. 
 
 
 
 We began with the synthesis of 25 because it is the simpler piece of the molecule; 
these reactions are shown in Scheme 4.2.  The first step was the N-alkylation of 5-
nitromethylindole using sodium hydride and methyl iodide.  This reaction is basically the 
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same as in our previous syntheses of N-methyl tryptophan and the small molecule 
MDM2 inhibitors described in Chapter Three.  The next step would be to reduce the nitro 
group to an amine via hydrogenation. This is a well-known literature procedure (25-27), 
but we have not yet performed it on compound 28 due to potential difficulties with 
storing it. 
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Scheme 4.2: Synthesis of Indole 25.  Compound 25 could readily be synthesized from 
commercially available nitroindole 27.  We did not complete the final step of the 
synthesis while we were attempting the synthesis of 26. 
 
 
 
 We then turned our attention to synthesizing 26, the other half of the molecule.  
Our initial plan was to begin with 2-methyl-5-nitroaniline 29 and reductively aminate it 
using 2,5-dimethoxytetrahydrofuran 30 to form tertiary aniline 31.  Compound 30 is a 
diacetal that we planned to open by adding acid, after which we would proceed with our 
normal reductive amination procedures as in Chapter Two.  We would then oxidize the 
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methyl group up to the carboxylic acid, and reduce the nitro to the amine.  Unfortunately, 
several attempts at conducting a reductive amination were all unsuccessful, as shown in 
Scheme 4.3.  We initially tried using acetic acid, a weak acid.  When that reaction failed, 
we attempted to use p-toluenesulfonic acid.  This reaction also failed, as did a third 
attempt using 2N HCl. 
 
NH2
NO2
29
O
OO X
N
NO2
AcOH
1.   MeOH
2.   NaBH3CN
30 31
NH2
NO2
29
O
OO X
N
NO2
1.   MeOH
2.   NaBH3CN
30 31
p-TsOH
NH2
NO2
29
O
OO X
N
NO2
1.   MeOH
2.   NaBH3CN
30 31
2N HCl
 
 
 
Scheme 4.3: Failed Attempts to Synthesize 31 via Reductive Amination of 29.  
Several acids were tried, including acetic, catalytic p-toluenesulfonic, stoichiometric p-
toluenesulfonic, and hydrochloric acids. 
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 We next attempted to synthesize compound 31 via an N,N-dialkylation using 1,4-
dibromobutane.  Our first attempt used DIEA in toluene following a literature procedure 
(28), which was not successful in our hands.  This failure is probably due to the high 
electron-withdrawing capacity of the nitro group on the benzene ring of 29, which greatly 
reduces the nucleophilicity of the aniline nitrogen.  The reported literature examples 
either had electron-donating groups or weaker electron-withdrawing groups attached to 
the benzene ring, but no examples of aniline dialkylation with a nitrobenzene were 
reported (28).  However, when we attempted the reaction again using potassium 
carbonate and the phase transfer catalyst TBAB (29), we were able to successfully obtain 
31.  These reactions are both shown in Scheme 4.4. 
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Scheme 4.4: Successful Synthesis of 31 via N, N-Dialkylation.  The first attempt to 
synthesize 31 gave only starting materials, but addition of TBAB, a phase transfer 
catalyst, and use of potassium carbonate gave 31 as a bright orange solid. 
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Scheme 4.5: Unsuccessful Attempts to Oxidize 29 and 31 to the Carboxylic Acids.  
Regardless of whether the amine was tertiary or primary, the methyl groups in 29 and 31 
could not be oxidized up to the corresponding acids in the presence of the amine.  
However, the oxidation reaction did proceed normally on toluene derivative 34, which 
lacks the amino group, to give acid 35. 
 
 
 
 Having obtained the tertiary aniline 31, we next attempted to oxidize the methyl 
group up to carboxylic acid 32 using potassium permanganate.  This reaction is also a 
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common, well-known literature procedure (30, 31).  However, we were not able to 
successfully obtain product 32 after several attempts at oxidizing 31.  Attempting the 
procedure on the initial starting material primary aniline 29 was also unsuccessful.  We 
were, however, able to successfully oxidize p-chlorotoluene 34 to the corresponding 
benzoic acid.  This suggested that our reagents were fine, and that somehow the presence 
of the aniline group was problematic.  We were furthermore able to rule out the nitro 
group as being the problem because one literature procedure reported the successful 
oxidation of a nitrotoluene to the corresponding nitrobenzoic acid (29).  These reactions 
are shown in Scheme 4.5. 
 Since we were unable to oxidize the methyl group in the presence of the amine, it 
was necessary to find an alternative route to synthesize 32.  We found another literature 
procedure where the methyl group had been oxidized in the presence of an acetylated 
amine (32).  Thus, our next strategy was to acetylate the aniline first, and then oxidize the 
methyl to a carboxylic acid.  This could be protected as an ester, after which the aniline 
could be deacetylated and then reacted with 1,4-dibromobutane to give 32. 
 We were able to successfully synthesize the acetylated aniline 36 using acetic 
anhydride and acetic acid (33,34), and oxidation of the methyl group with potassium 
permanganate gave benzoic acid 37.  We then protected 37 as the methyl ester using 
methyl iodide to give 38, and hydrolyzed the amide back to the free aniline 39a using 
HCl (35).  However, when we attempted to perform the dialkylation reaction on 39a to 
give tertiary aniline 39b, we found that no reaction would occur, even in the presence of 
TBAB.  Again, this is likely to be due to the presence of an additional electron-
withdrawing group on the benzene ring.  Before the methyl group was oxidized, it was 
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mildly activating.  However, once it was oxidized to the acid or ester, it became 
deactivating.  This series of reactions is shown in Scheme 4.6. 
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Scheme 4.6: Unsuccessful Attempt to N,N-Dialkylate a Benzoic Ester.  Acetylation of 
the amine allowed oxidation of the methyl group with KMnO4, but N,N-dialkylation of 
the ester was not successful due to the extremely low nucleophilicity of the aniline 
nitrogen. 
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 At this point, we attempted to perform another reductive amination of starting 
compound 29 using 2.5 M sulfuric acid and sodium borohydride in THF and methanol, 
following a literature procedure (36).  These reaction conditions were powerful enough to 
allow the reductive amination of 29 to give compound 31 in good yield.  However, when 
we attempted to repeat this procedure on aniline 38, there was no reaction.  Again, this is 
likely to be due to the low nucleophilicity of 38, which possesses two powerful electron-
withdrawing groups attached to the benzene ring in contrast to the weakly electron-
donating methyl group that is present on 29.  The procedure for reductive amination 
using sulfuric acid is shown in Scheme 4.7. 
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Scheme 4.7: Unsuccessful Attempt to Perform Reductive Amination on 38.  
Although several earlier attempts to do reductive amination had failed, the reaction was 
finally performed successfully on 29 using 2.5M H2SO4.  However, the reaction failed 
when it was attempted on compound 38. 
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Scheme 4.8: Synthesis of Succinimide 41 from Aniline 29.  Using succinyl chloride 
was messy and led to multiple products, but a small amount of product 41 could be 
obtained.  Succinic anhydride gave the product if refluxed, along with a side product that 
was initially thought to be the incomplete cyclization product.  This side product could 
not be cyclized using peptide coupling agents, and it was later determined to be the 
acetylated aniline 36. 
 
 
 
 Our next strategy was to attempt to synthesize the succinimide 41, which would 
be followed by oxidation of the methyl group to the carboxylic acid and then reduction of 
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the imide and nitro groups.  We predicted that the succinimide, like the acetylated aniline, 
should not interfere with the permanganate oxidation of the methyl group into the 
carboxylic acid.  Our first attempt to synthesize the succinimide by refluxing succinic 
anhydride in dioxane was not successful.  We then attempted to synthesize 41 using 
succinyl chloride; this reaction did produce a small amount of product, but the yield was 
poor and the reaction was messy and difficult to purify.  Finally, we followed a literature 
procedure (37) to make 41 from succinic anhydride by refluxing it in acetic acid.  This 
reaction turned out to be the most successful, and all of these procedures are shown in 
Scheme 4.8. 
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Scheme 4.9: Side Product of the Succinimide Reaction.  We concluded by NMR and 
TLC that the other major product of this reaction was acetanilide 36. 
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 However, even the second succinic anhydride procedure was still relatively low-
yielding, and TLC showed the presence of a second major spot present in about the same 
proportion as the desired product 41.  NMR and TLC tests allowed us to conclude that 
this side product was actually 36, the acetylated aniline that we had already synthesized 
previously.  This is not ultimately surprising, since the succinimide-forming conditions 
are similar to the acetylating conditions (33,34).  The literature yield for this reaction was 
also relatively low at 36% (37).  The reaction and both products formed are depicted in 
Scheme 4.9. 
 At this point, we had obtained sufficient quantities of 41 to allow us to continue 
with the synthesis.  The separation of 41 from 36 is relatively difficult since the two 
products run fairly close together on TLC, but we were able to separate them by 
chromatographing them in dichloromethane.  41 has a higher Rf compared with 36, and 
by using 100% DCM as the eluent, it is possible to collect 41 while 36 remains on the 
silica.  36 can be isolated by adding a small percentage of methanol to the DCM.  41 was 
then oxidized to carboxylic acid 42.  This reaction proceeded successfully as we expected 
based on our previous experience with oxidizing the acetylated aniline.   
 The next step in the synthesis is the reduction of the acid, imide, and nitro groups 
using lithium aluminum hydride to the primary alcohol, tertiary amine, and primary 
amine, respectively.  Then, the alcohol will be oxidized back to the carboxylic acid using 
Jones reagent to give 26, which can then be combined with 25 to give 44, the 
symmetrical half of 24.  These reactions are shown in Scheme 4.10.  Finally, the free 
amines on 44 can be connected together as a urea to give target molecule 24, as discussed 
previously.   
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Scheme 4.10: Proposed Synthesis of 44 from 41.  Compound 44 would then be used to 
synthesize target compound 24.  The synthesis of 43 was successfully completed. 
 
 
 
Should this series of reactions not be successful, we propose to attempt an 
alternative route where we would form the pyrrolidine either by dialkylating the aniline 
ring of 29 using 1,4-dibromobutane or by reductive amination.  We would then convert 
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the methyl group to the primary alcohol using wet NBS, followed by oxidation of alcohol 
45 to acid 46 with Jones reagent.  46 could then be hydrogenated to give intermediate 26, 
as shown in Scheme 4.11.  The first reaction in this procedure to form 31 has already 
been successfully accomplished as described previously. 
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Scheme 4.11: Alternative Proposed Route to Compound 26.   This route will be 
attempted next if the proposed route in Scheme 4.10 is unsuccessful. 
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 In conclusion, we have successfully used GLIDE docking simulations to virtually 
screen a library of NCI compounds, and we developed target compound 24 based on 
multiple screening iterations.  We then made significant progress on the synthesis of 24.  
Further work will entail completing the synthesis described above, as well as performing 
biological testing on 24. 
 
Experimental Data:  
 
 
28
N
NO2
 
Procedure for Synthesis of N-Methyl-5-Nitroindole (28).  Sodium hydride (0.925 
mmol) was washed twice with dry DMF, and then suspended in a third aliquot of dry 
DMF.  The reaction mixture was cooled to 0° C, and 5-nitroindole (0.671 mmol) was 
added slowly.  The reaction was then warmed up to room temperature and stirred for 15 
minutes under Ar, after which methyl iodide (0.678 mmol) was added dropwise via 
syringe.  The reaction was stirred for thirty minutes at RT, and TLC then showed that it 
was complete.  Ethyl acetate was added to the reaction, and it was then washed with dI 
water.  The water was back-extracted with ethyl acetate, and the combined ethyl acetate 
layers were washed once with water and twice with brine, dried over MgSO4, and 
evaporated under reduced pressure to give 28, a yellow solid, in 100% yield.  MP = 160-
162 °C; Rf = 0.32 (3:1 hexane/EtOAc); 1H NMR (400 MHz, CDCl3) δ 3.85 (s, 3H), 6.66 
(d, J = 2.8 Hz, 1H), 7.20 (d, J = 2.8 Hz, 1H), 7.32 (d, J = 8.8 Hz, 1H), 8.10 (d, J = 9.2 Hz, 
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1H), 8.56 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 33.43, 103.95, 109.22, 117.33, 118.25, 
127.74, 132.18, 139.55, 141.67; HR ESI-MS (0.1% AcOH in CH3CN) 177.06553 (M + 
H)+; (The compound begins to decompose above 100 °C.) 
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Procedure for Dialkylation Synthesis of 2-Pyrollidino-4-Nitrotoluene (31).  1-
methyl-5-nitroaniline (0.657 mmol) was dissolved in 5 mL toluene, and 1,4-
dibromobutane (0.657 mmol), potassium carbonate (0.657 mmol), and TBAB (0.066 
mmol) were added.  The reaction was then refluxed overnight and worked up by washing 
it with 2N HCl and back-extracting the aqueous layer with DCM.  The DCM was back-
extracted with 2N HCl three times, and then all of the aqueous layers were combined and 
basified with solid NaOH.  The aqueous layer was extracted five times with DCM, and 
these five organic layers were combined, dried over magnesium sulfate, and evaporated 
under reduced pressure.  Column chromatography using 9:1 hexanes/ethyl acetate gave 
31, an orange solid, in 59.3% yield.  MP = 73-74 °C; Rf = 0.68 (3:1 hexane/EtOAc); 1H 
NMR (400 MHz, CDCl3) δ 1.96-2.00 (m, 4H), 2.40 (s, 3H), 3.27-3.29 (m, 4H), 7.18 (d, J 
= 8.0 Hz, 1H), 7.62-7.64 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 21.48, 25.48, 109.98, 
114.58, 132.22, 135.52, 147.16, 150.35; ESI-MS (0.1% AcOH in CH3CN) 207.1 (M + 
H)+. 
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Procedure for Reductive Amination Synthesis of 2-Pyrollidino-4-Nitrotoluene (31).  
2,5-dimethoxytetrahydrofuran (2.32 mmol) was dissolved in THF, and reacted with 2.5 
M sulfuric acid (4.50 mmol).  The reaction mixture was cooled to 0 °C and stirred for 15 
minutes.  In a separate flask, 1-methyl-5-nitroaniline (1.77 mmol) was dissolved in a 1:1 
methanol/THF mixture and cooled to 0 °C.  The acidic acetal solution was then placed 
into an addition funnel, and this solution was added to the aniline reaction mixture 
dropwise.  The combined reaction mixture was stirred at 0 °C for 15 minutes, and then 
sodium borohydride was added from a powder addition funnel over twenty minutes.  The 
reaction was then warmed up to room temperature and stirred for an hour, after which it 
was quenched with NaOH and water, and extracted with DCM.  Chromatography in 9:1 
hexanes/ethyl acetate gave 31 as a bright orange powdery solid in 59.5% yield.  MP = 74-
75 °C; Rf = 0.63 (3:1 hexane/EtOAc); 1H NMR (400 MHz, CDCl3) δ 1.96-1.99 (m, 4H), 
2.40 (s, 3H), 3.27-3.30 (m, 4H), 7.17 (d, J = 8.0 Hz, 1H), 7.60 (s, 1H), 7.62 (d, J = 8.0 
Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 21.48, 25.48, 51.30, 109.99, 114.58, 132.22, 
135.52, 150.35; ESI-MS (0.1% AcOH in CH3CN) 207.1 (M + H)+. 
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Procedure for Synthesis of N-Acetyl-2-Amino-4-Nitrotoluene (36).  Aniline 29 
(0.0329 mol) was dissolved in 5 mL acetic acid, to which was added 8 mL acetic 
anhydride.  The flask was placed in a water bath at 45 °C, causing it to solidify.  25 mL 
chloroform was added, and the reaction was stirred at 45 °C for 10 minutes, until the SM 
had dissolved to form a reddish-brown solution.  The chloroform was removed under 
reduced pressure, and the product was recrystallized from a 1:1 solution of ethanol:water 
to give white, flowery crystals in a 68.6% yield.  MP = 149-150.5 °C; Rf = 0.56 (3:1 
hexane/EtOAc); 1H NMR (400 MHz, CDCl3) δ 2.27 (s, 3H), 2.37 (s, 3H), 7.07 (broad, 
1H), 7.34 (d, J  = 8.8 Hz, 1H), 7.94 (d, J  = 8.0 Hz, 1H), 8.78 (s, 1H); 13C NMR (100 
MHz, CDCl3) δ 18.12, 24.31, 118.05, 119.78, 130.97, 136.35, 136.48, 146.76, 168.57; 
ESI-MS (0.1% AcOH in CH3CN) 193.0 (M - H)-. 
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Procedure for Synthesis of N-Acetyl-2-Amino-4-Nitrobenzoic Acid (37).  Acetyl 
aniline 36 (0.476 mmol) was suspended in 10 mL dI water, to which magnesium sulfate 
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(0.297 mmol) was added.  The reaction flask was fitted with a condenser, and heated to 
80 °C, after which potassium permanganate (1.19 mmol) was added.  The reaction was 
stirred at 85 °C for one hour, then cooled to RT.  Small portions of sodium bisulfite and 
concentrated sulfuric acid were added until the solid manganese dioxide byproduct 
dissolved and the product 37 precipitated out of solution as a pale peachy yellow powder 
in 75.5 % yield.  MP = 197-198 °C; Rf = 0.22 (100% EtOAc); 1H NMR (400 MHz, 
CD3OD) δ 2.24 (s, 3H), 7.90-7.93 (m, 1H), 8.23-8.26 (m, 1H), 9.44 (s, 1H); 13C NMR 
(100 MHz, CD3OD) δ 23.84, 114.55, 116.60, 119.97, 131.13, 132.69, 142.10, 169.53; 
ESI-MS (0.1% AcOH in CH3CN) 223.0 (M - H)-. 
 
N
NO2
H
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38  
Procedure for Synthesis of Methyl N-Acetyl-2-Amino-4-Nitrobenzoate (38).   
Benzoic acid 37 (0.416 mmol) was dissolved in 5 mL DMF, and the reaction was cooled 
to 0 °C.  Potassium carbonate (0.458 mmol) was added, and the reaction was stirred for 
ten minutes at 0 °C before adding methyl iodide (0.833 mmol).  Then the reaction was 
allowed to warm to RT and stirred for four hours at RT.  The reaction was diluted with 
ethyl acetate and washed with saturated sodium bicarbonate solution, dI water, and brine 
solution to give 37 as a yellow oil in 76.9% yield. Rf = 0.31 (3:1 hexane/EtOAc); 1H 
NMR (400 MHz, CDCl3) δ 2.29 (s, 3H), 4.00 (s, 3H), 7.87 (dd, J = 2.4 Hz, 8.8 Hz, 1H), 
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8.19 (d, J = 8.8 Hz, 1H), 9.59 (d, J = 2.0 Hz, 1H); 11.12 (broad, 1H); 13C NMR (100 
MHz, CDCl3) δ 25.45, 53.12, 115.26, 116.50, 119.05, 131.94, 142.40, 151.26, 167.36, 
169.28. 
 
NH2
NO2
O
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39a  
Procedure for Synthesis of Methyl 2-Amino-4-Nitrobenzoate (39a).  Acetyl aniline 
38 (0.323 mmol) was suspended in 7 mL absolute ethanol, to which was added 1.4 mL 
concentrated HCl.  The reaction was refluxed for 18 hours at 79 °C, after which it was 
soluble in ethanol.  The ethanol was removed under reduced pressure, and the crude 
product was suspended in dI water and basified with 1M NaOH until the pH was 6 to 
give a gelatinous yellow solid in 77.8 % yield.  Rf = 0.00 (3:1 hexane/EtOAc); 1H NMR 
(400 MHz, CDCl3) δ 3.92 (s, 3H), 6.06 (broad, 2H), 7.40 (d, J = 7.6 Hz, 1H), 7.51 (s, 
1H), 8.01 (d, J = 7.8 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 52.42, 110.30, 111.35, 
115.16, 133.05, 150.91, 151.58, 167.50; ESI-MS (0.1% AcOH in CH3CN) 197.0 (M + 
H)+. 
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Procedure for Succinyl Chloride Synthesis of 2-Succinimido-4-Nitrotoluene (41).  
Aniline 29 (3.29 mmol) was dissolved in 25 mL DCM, to which was added succinyl 
chloride (3.61 mmol) and TEA (6.57 mmol).  The reaction was stirred at RT for one hour, 
after which the solid byproduct formed was filtered off, and the supernatant was 
chromatographed on silica in 2:1 hexanes/EtOAc to give 41 as pale yellow crystals in a 
15.2% yield.  MP = 214-217 °C; Rf = 0.29 (1:1 hexane/EtOAc); 1H NMR (400 MHz, 
CDCl3) δ 2.27 (s, 3H), 2.99 (s, 4H), 7.51 (d, J = 8.8 Hz, 1H), 8.02 (d, J = 2.4 Hz, 1H), 
8.22 (dd, J  = 2.4 Hz, 8.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 18.49, 28.90, 124.11, 
124.48, 129.06, 131.14, 132.18, 144.08, 175.56. 
 
Procedure for Succinic Anhydride Synthesis of 2-Succinimido-4-Nitrotoluene (41) 
and Acetylated Side Product (36).   Aniline 29 (3.29 mmol) and succinic anhydride 
(6.57 mmol) were dissolved in glacial acetic acid, and the reaction was refluxed for two 
hours.  It was then cooled to RT, and extracted with saturated bicarbonate solution.  The 
crude product was chromatographed on silica in 1:1 hexanes/EtOAc to give succinimide 
product 41 as pale yellow crystals in 30.3% yield, and side product acetyl aniline 36 as a 
white powdery solid in 30% yield. 
 
N
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2-Succinimido-4-Nitrotoluene (41).  MP = 215-218 °C; Rf = 0.30 (9:1 DCM/MeOH), 
Rf = 0.33 (1:1 hexane/EtOAc); 1H NMR (400 MHz, CDCl3) δ 2.27 (s, 3H), 2.99 (s, 4H), 
7.52 (d, J = 8.8 Hz, 1H), 8.02 (d, J = 2.4 Hz, 1H), 8.22 (dd, J = 2.4 Hz, 8.4 Hz); 13C 
NMR (100 MHz, CDCl3) δ 18.47, 28.90, 124.11, 124.47, 132.17, 144.10, 146.99, 175.56.  
 
N
NO2
H
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36  
N-Acetyl-2-Amino-4-Nitrotoluene (36).  MP = 149-150 °C; Rf = 0.12 (9:1 DCM 
/MeOH); 1H NMR (400 MHz, CDCl3) δ 2.26 (s, 3H), 2.37 (s, 3H), 7.16 (broad, 1H), 7.34 
(d, J = 8.8 Hz, 1H), 7.93 (d, J = 8.8 Hz, 1H), 8.75 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 
18.33, 24.57, 118.20, 120.00, 131.18, 136.26, 136.71, 147.10, 168.58; ESI-MS (0.1% 
AcOH in CH3CN) 193.0 (M - H)-. 
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2-Succinimido-4-Nitrobenzoic Acid (43).  MP = 145-146 °C; Rf = 0.00 (100% DCM); 
1H NMR (400 MHz, DMSO) δ 2.56-2.59 (m, 2H), 2.67-2.70 (m, 2H), 7.95 (dd, J = 2.0 
Hz, 8.4 Hz, 1H), 8.20 (d, J = 8.4 Hz, 1H), 9.30 (d, J = 2.4 Hz, 1H), 11.22 (broad, 1H); 
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13C NMR (100 MHz, DMSO) δ 29.25, 32.78, 114.97, 117.52, 124.54, 133.31, 141.79, 
150.82, 168.77, 171.74, 174.19. 
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CHAPTER FIVE 
 
APPENDIX: PROTON AND CARBON NMR SPECTRA 
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